Experience in performing multivisceral resections for pelvic cancer ; Опыт выполнения мультивисцеральных резекций по поводу злокачественных новообразований органов малого таза

Authors: S. G. Afanasyev, E. A. Usynin, I. B. Khadagaev, S. A. Fursov, L. A. Kolomiets, A. V. Usova, I. G. Frolova, О. V. Cheremisina, С. Г. Афанасьев, Е. А. Усынин, И. Б. Хадагаев, С. A. Фурсов, Л. А. Коломиец, А. В. Усова, И. Г. Фролова, О. В. Черемисина

Source: Siberian journal of oncology; Том 23, № 6 (2024); 129-137 ; Сибирский онкологический журнал; Том 23, № 6 (2024); 129-137 ; 2312-3168 ; 1814-4861

Subject Terms: мультивисцеральные резекции, rectal cancer, bladder cancer, uterine tumors, recurrent ovarian cancer, synchronous primary multiple tumors, multivisceral resections, рак прямой кишки, рак мочевого пузыря, опухоли тела матки, рецидивный рак яичников, синхронные первично-множественные опухолей

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/3355/1299; Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6): 394–424. doi:10.3322/caac.21492. Erratum in: CA Cancer J Clin. 2020; 70(4): 313. doi:10.3322/caac.21609.; Шахзадова А.О., Старинский В.В., Лисичникова И.В. Состояние онкологической помощи населению России в 2022 году. Сибирский онкологический журнал. 2023; 22(5): 5–13. doi:10.21294/1814-4861-2023-22-5-5-13.; Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М., 2024. 276 с.; Рак. Всемирная организация здравоохранения [Internet]. URL: https://www.who.int/ru/news-room/fact-sheets/detail/cancer. [cited 2024 Sep 1].; Sung X., Ferlay Ja., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71 (3): 209–49. doi:10.3322/caac.21660.; Кононова Г.А., Жуйкова Л.Д., Ананина О.А., Коломиец Л.А., Пикалова Л.В., Жуйкова А.С. Рак репродуктивной системы у женщин Республики Тыва. Эпидемиологические особенности. Сибирский онкологический журнал. 2024; 23(3): 5–14. doi:10.21294/1814-4861-2024-23-3-5-14.; Карпенко М.О., Шостка К.Г., Загайнов Е.В., Шиляев А.В., Калинин И.В. Хирургические аспекты лечения местнораспространенного рака толстой кишки. Вопросы онкологии. 2024; 70(1): 105–112. doi:10.37469/0507-3758-2024-70-1-105-112.; Doyle D.J., Hendrix J.M., Garmon E.H. American Society of Anesthesiologists Classification. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan. 2023 Aug 17.; Каприн А.Д., Сулейманов Э.А., Калинин Е.В. Отдаленные результаты расширенных и комбинированных оперативных вмешательств у больных с местно-распространенными формами рака прямой кишки в зависимости от степени циторедукции. Онкология. Журнал им. П.А. Герцена. 2017; 3: 21–28. doi:10.17116/onkolog20176321-28.; Brown K.G.M., Solomon M.J, Koh C.E. Pelvic Exenteration Surgery: The Evolution of Radical Surgical Techniques for Advanced and Recurrent Pelvic Malignancy. Dis Colon Rectum. 2017 Jul; 60(7): 745–754. doi:10.1097/DCR.0000000000000839.; Kondo A., Sasaki T., Kitaguchi D., Tsukada Y., Nishizawa Y., Ito M. Resection of the urinary bladder for locally advanced colorectal cancer: a retrospective comparison of partial versus total cystectomy. BMC Surg. 2019 Jun 17; 19(1): 63. doi:10.1186/s12893-019-0522-8.; Черемисина О.В., Меньшиков К.Ю., Афанасьев С.Г., Вусик М.В. Предопухолевые изменения и синхронный рак желудка у больных со злокачественными новообразованиями легких и ЛОР-органов. Сибирский онкологический журнал. 2015; 2: 76–78.; Афанасьев С.Г., Хадагаев И.Б., Фурсов С.А., Усынин Е.А., Горбунов А.К., Урмонов У.Б., Усова А.В., Августинович А.В., Тарасова А.С. Опыт мультивисцеральных резекций при местнораспространенном и первично-множественном раке прямой кишки. Вестник Авиценны. 2020; 22(1): 82–90. doi:10.25005/2074-0581-2020-22-1-82-90.; Bolmstrand B., Nilsson P.J., Holm T., Buchli C., Palmer G. Patterns of complications following urinary tract reconstruction after multivisceral surgery in colorectal and anal cancer. Eur J Surg Oncol. 2018; 44(10): 1513–7. doi:10.1016/j.ejso.2018.06.017.; https://www.siboncoj.ru/jour/article/view/3355

Availability: https://www.siboncoj.ru/jour/article/view/3355
https://doi.org/10.21294/1814-4861-2024-23-6-129-137

New capabilities of 2nd and subsequent therapy lines in metastatic urothelial cancer ; Новые возможности терапии 2-й и последующих линий метастатического уротелиального рака

Authors: A. S. Kalpinskiy, O. A. Mailyan, А. С. Калпинский, О. А. Маилян

Source: Cancer Urology; Том 20, № 4 (2024); 75-89 ; Онкоурология; Том 20, № 4 (2024); 75-89 ; 1996-1812 ; 1726-9776

Subject Terms: энфортумаб ведотин, metastatic bladder cancer, enfortumab vedotin, метастатический рак мочевого пузыря

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1904/1577; Ferlay J., Ervik M., Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2024. Available at: https://gco.iarc.who.int/today; Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, О.В. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с.; Von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI:10.1200/JCO.2000.18.17.3068; De Santis M., Bellmunt J., Mead G. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/ vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J Clin Oncol 2012;30(2):191–9. DOI:10.1200/JCO.2011.37.3571; Bellmunt J., von der Maase H., Mead G.M. et al. Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 2012;30(10):1107–13. DOI:10.1200/JCO.2011.38.6979; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. DOI:10.1056/NEJMoa2002788; Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:1015–26. DOI:10.1056/NEJMoa1613683; Powles T., Durán I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391:748–57. DOI:10.1016/S0140-6736(17)33297-X; Knowles M.A., Hurst C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 2015;15(1):25–41. DOI:10.1038/nrc3817; Loriot Y., Necchi A., Park S.H. et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338–48. DOI:10.1056/NEJMoa1817323; Black P.C., Alimohamed N.S., Berman D. et al. Optimizing management of advanced urothelial carcinoma: a review of emerging therapies and biomarker-driven patient selection. Can Urol Assoc J 2020;14:E373–82. DOI:10.5489/cuaj.6458; Nadal R., Bellmunt J. Management of metastatic bladder cancer. Cancer TreatRev 2019;76:10–21. DOI:10.1016/j.ctrv.2019.04.002; Patel V.G., Oh W.K., Galsky M.D. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin 2020;70(5):404–23. DOI:10.3322/caac.21631; EAU Guidelines. Edn. presented at the EAU Annual Congress Paris 2024. ISBN 978-94-92671-23-3; Flaig T.W., Spiess P.E., Abern M. et al. NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw 2024;22(4):216–25. DOI:10.6004/jnccn.2024.0024; Tagawa S., Balar A.V., Petrylak D.P. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39(22):2474–85. DOI:10.1200/JCO.20.03489; Gilead provides update on U.S. indication for Trodelvy in metastatic urothelial cancer. News release. October 18, 2024. Accessed October 18, 2024. Available at: https://www.gilead.com/company/company-statements/2024/gilead-provides-update-on-us-indication-for-trodelvy-in-metastatic-urothelial-cancer; Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI:10.1200/JCO.2008.20.5534; Bellmunt J., Fougeray R., Rosenberg J.E. et al. Long-term survival results of a randomized phase III trial of vinflunine plus best supportive care versus best supportive care alone in advanced urothelial carcinoma patients after failure of platinum based chemotherapy. Ann Oncol 2013;24(6):1466–72. DOI:10.1093/annonc/mdt007; Dreicer R., Manola J., Schneider D.J. et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer 2003;97(11):2743–7. DOI:10.1002/cncr.11413; McCaffrey J.A., Hilton S., Mazumdar M. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15(5):1853–7. DOI:10.1200/JCO.1997.15.5.1853; Vaughn D.J., Broome C.M., Hussain M. et al. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002;20(4):937–40. DOI:10.1200/JCO.2002.20.4.937; Sridhar S.S., Blais N., Tran B. et al. Efficacy and safety of nab-paclitaxel vs paclitaxel on survival in patients with platinum-refractory metastatic urothelial cancer: the Canadian Cancer Trials Group BL.12 randomized clinical trial. JAMA Oncol 2020;6(11):1–8. DOI:10.1001/jamaoncol.2020.3927; Meric-Bernstam F., Makker V., Oaknin A. et al. Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: primary results from the DESTINY-PanTumor02 phase II trial. J Clin Oncol 2024;42(1):47–58. DOI:10.1200/JCO.23.02005; Challita-Eid P.M., Satpayev D., Yang P. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76:3003–13. DOI:10.1158/0008-5472.CAN-15-1313; Hoffman-Censits J.H., Lombardo K.A., Parimi V. et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol 2021;29(8):619–25. DOI:10.1097/PAI.0000000000000938; Zhang Y., Liu S., Wang L. et al. A novel PI3K/AKT signaling axis mediates nectin-4-induced gallbladder cancer cell proliferation, metastasis and tumor growth. Cancer Lett 2016;375:179–89. DOI:10.1016/j.canlet.2016.02.049; Zhang Y., Zhang J., Shen Q. et al. High expression of nectin-4 is associated with unfavorable prognosis in gastric cancer. Oncol Lett 2018;15:8789–95. DOI:10.3892/ol.2018.8365; Tomiyama E., Fujita K., Rodriguez Pena M.D.C. et al. Expression of nectin-4 and PD-L1 in upper tract urothelial carcinoma. Int J Mol Sci 2020;21(15):5390. DOI:10.3390/ijms21155390; Mantia C.M., Sonpavde G. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma. Expert Rev Anticancer Ther 2022;22(5):449–55. DOI:10.1080/14737140.2022.2069563; Инструкция к препарату Падцев Онко. Доступно по: https://www.vidal.ru/drugs/padtsev-onko; Rosenberg J., Sridhar S.S., Zhang J. et al. EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma. J Clin Oncol 2020;38:1041–9. DOI:10.1200/JCO.19.02044; Rosenberg J.E., O’Donnell P.H., Balar A.V. et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37:2592–600. DOI:10.1200/JCO.19.01140; Yu E.Y., Petrylak D.P., O’Donnell P.H. et al. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2021;22:872–82. DOI:10.1016/S1470-2045(21)00094-2; Balar A.V., McGregor B.A., Rosenberg J.E. et al. EV-201 cohort 2: enfortumab vedotin in cisplatin-i neligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors. J Clin Oncol 2021;39(suppl):394.; Powles T., Rosenberg J.E., Sonpavde G.P. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125–1135. DOI:10.1056/NEJMoa2035807; Rosenberg J.E., Powles T., Sonpavde G.P. et al. EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Ann Oncol 2023;34(11):1047–54. DOI:10.1016/j.annonc.2023.08.016; Rosenberg J.E., Mamtani R., Sonpavde G.P. et al. Health-related quality of life in patients with previously treated advanced urothelial carcinoma from EV-301: a phase 3 trial of enfortumab vedotin versus chemotherapy. Eur Urol 2024;85(6):574–85. DOI:10.1016/j.eururo.2024.01.007; Koshkin V.S., Henderson N., James M. et al. Efficacy of enfortumab vedotin in advanced urothelial cancer: analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. Cancer 2022;128(6):1145–345. DOI:10.1002/cncr.34057; https://oncourology.abvpress.ru/oncur/article/view/1904

Availability: https://oncourology.abvpress.ru/oncur/article/view/1904
https://doi.org/10.17650/1726-9776-2024-20-4-75-89

Effectiveness of pembrolizumab in therapy of sarcomatoid variant of metastatic urothelial carcinoma. Clinical case ; Эффективность пембролизумаба в терапии саркоматоидного варианта метастатической уротелиальной карциномы. Клинический случай

Authors: A. S. Polyakova, E. A. Sokolov, D. Yu. Pushkar, А. С. Полякова, Е. А. Соколов, Д. Ю. Пушкарь

Source: Cancer Urology; Том 20, № 4 (2024); 104-111 ; Онкоурология; Том 20, № 4 (2024); 104-111 ; 1996-1812 ; 1726-9776

Subject Terms: саркоматоидный рак, bladder cancer, immunotherapy, pembrolizumab, sarcomatoid carcinoma, рак мочевого пузыря, иммунотерапия, пембролизумаб

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1857/1579; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1570; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1571; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1572; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1573; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1574; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1575; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1576; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1857/1577; Lenis A.T., Lec P.M., Chamie K., Mshs M.D. Bladder cancer: a review. JAMA 2020;324(19):1980–91. DOI:10.1001/jama.2020.17598; Gu L., Ai Q., Cheng Q. et al. Sarcomatoid variant urothelial carcinoma of the bladder: a systematic review and meta­analysis of the clinicopathological features and survival outcomes. Cancer Cell Int 2020;20(1):550. DOI:10.1186/s12935­020­01626­9; Sui W., Matulay J.T., Onyeji I.C. et al. Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer. World J Urol 2017;35(7):1055–61. DOI:10.1007/s00345­016­1962­8; Konala V.M., Adapa S., Aronow W.S. Immunotherapy in bladder cancer. Am J Ther 2022;29(3):e334–7. DOI:10.1097/MJT.0000000000000934; Evans S.T., Jani Y., Jansen C.S. et al. Understanding and overcoming resistance to immunotherapy in genitourinary cancers. Cancer Biol Ther 2024;25(1):2342599. DOI:10.1080/15384047.2024.2342599; Bellmunt J., de Wit R., Vaughn D.J. et al. Pembrolizumab as second­ line line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI:10.1056/NEJMoa1613683; Miller N.J., Khaki A.R., Diamantopoulos L.N. et al. Histological subtypes and response to PD­1/PD­L1 blockade in advanced urothelial cancer: a retrospective Study. J Urol 2020;204(1):63–70. DOI:10.1097/JU.0000000000000761; Kobayashi T., Ito K., Kojima T. et al.; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci 2021;112(2):760–73. DOI:10.1111/cas.14762; Iacovelli R., Ciccarese C., Bria E. et al. Patients with sarcomatoid renal cell carcinoma – re­defining the first­line of treatment: a meta­analysis of randomised clinical trials with immune checkpoint inhibitors. Eur J Cancer 2020;136:195–203. DOI:10.1016/j.ejca.2020.06.008; Kotlowska M.P., Rueda A.G., Olmedo M.E. et al. Efficacy of immunotherapy in sarcomatoid lung cancer, a case report and literature review. Respir Med Case Rep 2019;26:310–4. DOI:10.1016/j.rmcr.2019.02.017; Tsurumi K., Kawashima Y., Akahira J. et al. A remarkable clinical response to pembrolizumab in a rare spindle cell carcinoma of the lung. JMA J 2020;3(1):83–6. DOI:10.31662/jmaj.2019­0015; Jin C., Yang B. Dramatic response of pulmonary sarcomatoid carcinoma to nivolumab combined with anlotinib: a case report. Case Rep Oncol 2020;13(2):601–5. DOI:10.1159/000507568; Li H., Zhang Q., Shuman L. et al. Evaluation of PD­L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 2020;10(1):1439. DOI:10.1038/s41598­020­58351­6; Murase K., Nakane K., Kawase M. et al. Metastatic urothelial carcinoma with sarcomatoid subtype after robot­assisted radical cystectomy successfully treated with pembrolizumab. Cureus 2024;16(6):e61871. DOI:10.7759/cureus.61871; https://oncourology.abvpress.ru/oncur/article/view/1857

Availability: https://oncourology.abvpress.ru/oncur/article/view/1857
https://doi.org/10.17650/1726-9776-2024-20-4-104-111

VEGF gene polymorphisms and as a potential roles of bladder cancer recurrence factor ; Полиморфизм гена VEGF и его потенциальная роль фактора риска рецидива рака мочевого пузыря

Authors: G. P. Siregar, I. Parwati, F. Safridai, T. Tjahjodjati, F. Safriadi

Source: Cancer Urology; Том 20, № 4 (2024); 120-126 ; Онкоурология; Том 20, № 4 (2024); 120-126 ; 1996-1812 ; 1726-9776

Subject Terms: рецидив, bladder cancer, recurrence, рак мочевого пузыря

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1825/1588; Kaseb H., Aeddula N.R. Bladder Cancer. [Updated 2022 Oct 24]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing, 2024. Available at: https://www.ncbi.nlm.nih.gov/books/NBK536923/; Humphrey P.A., Moch H., Cubilla A.L. et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and BladderTumours. Eur Urol 2016;70(1):106–19. DOI:10.1016/j.eururo.2016.02.028; Fu D., Li P., Cheng W. et al. Impact of vascular endothelial growth factor gene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population. Oncotarget 2017;8(14):22927–35. DOI:10.18632/oncotarget.15287; Ferrara N. Vascular endothelial growth factors as a target for anticancer therapy. Oncologist 2004;9:2–10. DOI:10.1634/theoncologist.9-suppl_1-2; Siregar G.P. Vascular endothelial growth factor polymorphism in bladder cancer: areview. Open Access Macedonian Journal of Medical Sciences (OAMJMS) 2020;8(F):31–6.; Van der Horst G., Bos L., van der Pluijm G. Epithelial plasticity, cancer stem cells, and the tumor-supportive stroma in bladder carcinoma. Mol Cancer Res 2012;10(8):995–1009. DOI:10.1158/1541-7786.MCR-12-0274; Bakkar A.A., Wallerand H., Radvanyi F. et al. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res 2003;63(23):8108–12.; Chan K.S., Espinosa I., Chao M. et al. Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. PNAS 2009;106(33): 14016–21. DOI:10.1073/pnas.0906549106; Thompson D.B., Siref L.E., Feloney M.P. et al. Immunological basis in the pathogenesis and treatment of bladder cancer. Expert Rev Clin Immunol 2015;11(2):265–79. DOI:10.1586/1744666X.2015.983082; Marti H.H. Vascular Endothelial Growth Factor. In: Madame Curie Bioscience Database [Internet]. Austin (TX): Landes Bioscience; 2000–2013. Available at: https://www.ncbi.nlm.nih.gov/books/NBK6149/; Clauss M. Molecular biology of the VEGF and the VEGF receptor family. Semin Thromb Hemost 2000;26(5):561–9. DOI:10.1055/s-2000-13213; Robinson C.J., Stringer S.E. The splice variants of vascular endothelial growth factor (VEGF)and their receptors. J Cell Sci 2001;114:853–65. DOI:10.1242/jcs.114.5.853; Marti H.H., Risau W. Angiogenesis in ischemic disease. Thromb Haemost 1999;82 Suppl 1:44–52.; Wenger R.H. Mammalian oxygen sensing, signalling and gene regulation. J Exp Biol 2000;203:1253–63.; Wafi S.B., Kallel A., Fradj M.K. et al. Haplotype-based association of vascular endothelial growth factor gene polymorphisms with urothelial bladder cancer risk in Tunisian population. J Clin Lab Anal 2018;32(9):e22610. DOI:10.1002/jcla.22610; Cohen S.M., Shirai T., Steineck G. Epidemiology and etiology of premalignant and malignanturothelial changes. Scand J Urol Nephrol Suppl 2000;205:10515. DOI:10.1080/00365590050509869; Garcia-Closas M., Malats N., Real F.X. et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms andbladder cancer risk. Plos Genetics 2007;3(2):287–93. DOI:10.1371/journal.pgen.0030029; Fu D., Li P., Cheng W. et al. Impact of vascular endothelial growth factorgene-gene and gene-smoking interaction and haplotype combination on bladder cancer risk in Chinese population. Oncotarget 2017;8(14):22927–35. DOI:10.18632/oncotarget.15287; Jaiswal P.K., Tripathi N., Shukla A., Mittal R.D. Association of single nucleotide polymorphismsin vascular endothelial growth factor gene with bladder cancer risk. Med Oncol 2013;30(2):509–16. DOI:10.1007/s12032-013-0509-8; Yang Y., Zhang X., Song D., Wei J. Association between vascular endothelial growth factor gene polymorphisms and bladder cancer risk. Mol Clin Oncol 2014;2(4):501–5. DOI:10.3892/mco.2014.296; Longo F., Biondi M.L., Inneo V. et al. Vascular endothelial growth factor (VEGF) genotypes, halotypes and risk of bladder cancer. Eur Urol Suppl 2009;8(4):227.; Henriquez-Hernandez L.A., Navarro P., Luzardo O.P. et al. Polymorphisms of glutathione S-transferase and, MDR1 and VEGF genes as riskfactors of bladder cancer: A case-control study. Urol Oncol 2012;30(5):660–5. DOI:10.1016/j.urolonc.2010.08.02; https://oncourology.abvpress.ru/oncur/article/view/1825

Availability: https://oncourology.abvpress.ru/oncur/article/view/1825
https://doi.org/10.17650/1726-9776-2024-20-4-120-126

МЕТОДЫ АНАЛИЗА ВЫЖИВАЕМОСТИ ПАЦИЕНТОВ ПОСЛЕ РАДИКАЛЬНОЙ ЦИСТЭКТОМИИ

Subject Terms: Kaplan-Meier curves, classification trees, рак мочевого пузыря, деревья классификации, bladder cancer, кривые Каплана-Мейера, радикальная цистэктомия, выживаемость, radical cystectomy, survival, 3. Good health

APPLICATION OF GRAPHICAL METHODS IN THE ANALYSIS OF SURVIVAL OF PATIENTS WITH BLADDER CANCER

Source: Экологические системы и приборы.

Subject Terms: ФАКТОРЫ РИСКА, РАК МОЧЕВОГО ПУЗЫРЯ, РАДИКАЛЬНАЯ ЦИСТЭКТОМИЯ, ИНДЕКС КОМОРБИДНОСТИ CHARLSON, CHARLSON COMORBIDITY INDEX, RISK FACTORS, ВЫЖИВАЕМОСТЬ, КУРЕНИЕ, RADICAL CYSTECTOMY, SMOKING, BLADDER CANCER

Urine microbiota in non-muscle-invasive bladder cancer and approaches to its detection ; Микробиота мочи при немышечно-инвазивном раке мочевого пузыря и подходы к её выявлению

Authors: M. I. Kogan, Yu. L. Naboka, A. V. Ryzhkin, I. A. Gudima, A. G. Ivanov, S. N. Ivanov, O. N. Vasiliev, V. P. Glukhov, A. V. Ilyash, D. V. Sizyakin, М. И. Коган, Ю. Л. Набока, А. В. Рыжкин, И. А. Гудима, А. Г. Иванов, С. Н. Иванов, О. Н. Васильев, В. П. Глухов, А. В. Ильяш, Д. В. Сизякин

Source: Urology Herald; Том 12, № 3 (2024); 53-61 ; Вестник урологии; Том 12, № 3 (2024); 53-61 ; 2308-6424 ; 10.21886/2308-6424-2024-12-3

Subject Terms: воспаление, non-muscle invasive bladder cancer, microbiota, urinary tract infection, inflammation, немышечно-инвазивный рак мочевого пузыря, микрбиота, инфекция мочевых путей

File Description: application/pdf

Relation: https://www.urovest.ru/jour/article/view/881/562; Deng Z, Tang N, Xiong W, Lei X, Zhang T, Yang N. Inflammation-related research within the field of bladder cancer: a bibliometric analysis. Front Oncol. 2023;13:1126897. DOI:10.3389/fonc.2023.1126897; Vermeulen SH, Hanum N, Grotenhuis AJ, Castaño-Vinyals G, van der Heijden AG, Aben KK, Mysorekar IU, Kiemeney LA. Recurrent urinary tract infection and risk of bladder cancer in the Nijmegen bladder cancer study. Br J Cancer. 2015;112(3):594-600. DOI:10.1038/bjc.2014.601; Huang CH, Chou YH, Yeh HW, Huang JY, Yang SF, Yeh CB. Risk of Cancer after Lower Urinary Tract Infection: A Population-Based Cohort Study. Int J Environ Res Public Health. 2019;16(3):390. DOI:10.3390/ijerph16030390; Pottegård A, Kristensen KB, Friis S, Hallas J, Jensen JB, Nørgaard M. Urinary tract infections and risk of squamous cell carcinoma bladder cancer: A Danish nationwide case-control study. Int J Cancer. 2020;146(7):1930-1936. DOI:10.1002/ijc.32842; Kogan MI, Naboka YL, Ibishev KS, Gudima IA, Naber KG. Human urine is not sterile - shift of paradigm. Urol Int. 2015;94(4):445-552. DOI:10.1159/000369631; Набока Ю.Л., Рымашевский А.Н., Коган М.И., Гудима И.А., Боровлева О.А., Джалагония К.Т., Заруцкий С.А. Микробиота мочи и влагалища здоровых женщин постменопаузального возраста (пилотное исследование). Урология. 2016;(1):13-19. eLIBRARY ID: 25849372 EDN: VTRFED; Hilt EE, McKinley K, Pearce MM, Rosenfeld AB, Zilliox MJ, Mueller ER, Brubaker L, Gai X, Wolfe AJ, Schreckenberger PC. Urine is not sterile: use of enhanced urine culture techniques to detect resident bacterial flora in the adult female bladder. J Clin Microbiol. 2014;52(3):871-876. DOI:10.1128/JCM.02876-13; Hochstedler BR, Burnett L, Price TK, Jung C, Wolfe AJ, Brubaker L. Urinary microbiota of women with recurrent urinary tract infection: collection and culture methods. Int Urogynecol J. 2022;33(3):563-570. DOI:10.1007/s00192-021-04780-4; Brubaker L, Wolfe AJ. The female urinary microbiota, urinary health and common urinary disorders. Ann Transl Med. 2017;5(2):34. DOI:10.21037/atm.2016.11.62; Thomas-White KJ, Kliethermes S, Rickey L, Lukacz ES, Richter HE, Moalli P, Zimmern P, Norton P, Kusek JW, Wolfe AJ, Brubaker L; National Institute of Diabetes and Digestive and Kidney Diseases Urinary Incontinence Treatment Network. Evaluation of the urinary microbiota of women with uncomplicated stress urinary incontinence. Am J Obstet Gynecol. 2017;216(1):55.e1-55.e16. DOI:10.1016/j.ajog.2016.07.049; Johansen TEB, Wagenlehner FME, Cho YH, Matsumoto T, Krieger JN, Shoskes D, Naber K. Urogenital Infections and Inflammations. Arnhem: European Association of Urology; 2015.; Состояние онкологической помощи населению России в 2022 году. Под ред. Каприна А.Д., Старинского В.В., Шахзадовой А.О. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИРЦ» Минздрава России, 2023.; Клинические рекомендации «Бактериологический анализ мочи». М., 2014.; Коган М.И., Набока Ю.Л., Гудима И.А., Рымашевский А.Н., Воробьева Н.В., Рымашевский М.А. Микробиота свежевыделенной средней порции мочи у женщин в I триместре беременности (пилотное исследование). Проблемы репродукции. 2023;29(5):73‑78. DOI:10.17116/repro20232905173; Lewis DA, Brown R, Williams J, White P, Jacobson SK, Marchesi JR, Drake MJ. The human urinary microbiome; bacterial DNA in voided urine of asymptomatic adults. Front Cell Infect Microbiol. 2013;3:41. DOI:10.3389/fcimb.2013.00041; Brubaker L, Wolfe AJ. The new world of the urinary microbiota in women. Am J Obstet Gynecol. 2015;213(5):644-649. DOI:10.1016/j.ajog.2015.05.032; Набока Ю.Л., Коган М.И., Васильева Л.И., Гудима И.А., Мирошниченко Е.А., Ибишев Х.С. Бактериальная микст-инфекция у женщин с хроническим рецидивирующим циститом. Журнал микробиологии, эпидемиологии и иммунобиологии. 2011;(1):8-12. eLIBRARY ID: 19059389; EDN: QBBZQF; Pearce MM, Zilliox MJ, Rosenfeld AB, Thomas-White KJ, Richter HE, Nager CW, Visco AG, Nygaard IE, Barber MD, Schaffer J, Moalli P, Sung VW, Smith AL, Rogers R, Nolen TL, Wallace D, Meikle SF, Gai X, Wolfe AJ, Brubaker L; Pelvic Floor Disorders Network. The female urinary microbiome in urgency urinary incontinence. Am J Obstet Gynecol. 2015;213(3):347.e1-11. DOI:10.1016/j.ajog.2015.07.009; Коган М.И., Набока Ю.Л., Рыжкин А.В., Васильев О.Н. Микробиота/микробиом мочи и рак мочевого пузыря. Онкоурология. 2020;16(2):97-103. DOI:10.17650/1726-9776-2020-16-2-97-103; Bučević Popović V, Šitum M, Chow CT, Chan LS, Roje B, Terzić J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. DOI:10.1038/s41598-018-29054-w; Manoni F, Gessoni G, Alessio MG, Caleffi A, Saccani G, Silvestri MG, Poz D, Ercolin M, Tinello A, Valverde S, Ottomano C, Lippi G. Mid-stream vs. first-voided urine collection by using automated analyzers for particle examination in healthy subjects: an Italian multicenter study. Clin Chem Lab Med. 2011;50(4):679-684. DOI:10.1515/cclm.2011.823; Hourigan SK, Zhu W, S W Wong W, Clemency NC, Provenzano M, Vilboux T, Niederhuber JE, Deeken J, Chung S, McDaniel-Wiley K, Trump D. Studying the urine microbiome in superficial bladder cancer: samples obtained by midstream voiding versus cystoscopy. BMC Urol. 2020;20(1):5. DOI:10.1186/s12894-020-0576-z; https://www.urovest.ru/jour/article/view/881

Availability: https://www.urovest.ru/jour/article/view/881
https://doi.org/10.21886/2308-6424-2024-12-3-53-61

Minimally invasive treatment of urothelial carcinoma of the upper urinary tract: clinical case ; Малоинвазивное лечение уротелиального рака верхних мочевыводящих путей: клинический случай

Authors: V. V. Protoshchak, M. V. Paronnikov, E. G. Karpushchenko, A. V. Sleptsov, P. A. Babkin, N. P. Kushnirenko, R. V. Novikov, В. В. Протощак, М. В. Паронников, Е. Г. Карпущенко, А. В. Слепцов, П. А. Бабкин, Н. П. Кушниренко, Р. В. Новиков

Source: Cancer Urology; Том 20, № 1 (2024); 103-108 ; Онкоурология; Том 20, № 1 (2024); 103-108 ; 1996-1812 ; 1726-9776

Subject Terms: чрескожная резекция, tumor of the renal pelvis, bladder cancer, recurrence, progression, transcutaneous resection, опухоль лоханки, рак мочевого пузыря, рецидив, прогрессия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1699/1517; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1699/1374; Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71(3):209–49. DOI:10.3322/caac.21660; National Cancer Institute. SEER Stat Fact Sheets: Bladder Cancer, 2015 Available at: http://seer.cancer.gov/statfacts/html/urinb.html [cited March 6, 2015].; Cosentino M., Palou J., Gaya J.M. et al. Upper urinary tract urothelial cell carcinoma: location as a predictive factor for concomitant bladder carcinoma. World J Urol 2013;31(1):141–5. DOI:10.1007/s00345-012-0877-2; Margulis V., Shariat S.F., Matin S.F. et al. Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 2009;115(6):1224–33. DOI:10.1002/cncr.24135; Roupret M., Siesen T., Birtle A. et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol 2023;84(1):49–64. DOI:10.1016/j.eururo.2023.03.013; Rosenthal D.L., Wojcik E.M., Kurtycz D.F.I. The Paris System for reporting urinary cytology. Springer, 2016.; Мартов А.Г., Ергаков Д.В., Андронов А.С. Уротелиальный рак верхних мочевыводящих путей: возможно ли удаление опухоли единым блоком? Онкоурология 2022;18(3):123–7. DOI:10.17650/1726-9776-2022-18-3-123-127; Motamedinia P., Keheila M., Leavitt D.A. et al. The expanded use of percutaneous resection for upper tract urothelial carcinoma: a 30-year comprehensive experience. J Endourol 2016;30(3):262–7. DOI:10.1089/end.2015.0248; Lucas S.M., Svatek R.S., Olgin G. et al. Conservative management in selected patients with upper tract urothelial carcinoma compares favourably with early radical surgery. BJU Int 2008;102(2):172–6. DOI:10.1111/j.1464-410X.2008.07535.x; Belugina R., Kirsanov D., Protoshchak V. et al. Developing non-invasive bladder cancer screening methodology through potentiometric multisensor urine analysis. Talanta 2021;234:122696. DOI:10.1016/j.talanta.2021.122696; Habuchi T., Takahashi R., Yamada H. et al. Metachronous multifocal development of urothelial cancers by intraluminal seeding. Lancet 1993;342(8879):1087–8. DOI:10.1016/0140-6736(93)92066-3; Mistretta F.A., Carrion D.M., Nazzani S. et al. Bladder recurrence of primary upper tract urinary carcinoma following nephroureterectomy, and risk of upper urinary tract recurrence after ureteral stent positioning in patients with primary bladder cancer. Minerva Urol Nefrol 2019;71(3):191–200. DOI:10.23736/S0393-2249.19.03311-3; Jones T.D., Wang M., Eble J.N. et al. Molecular evidence supporting field effect in urothelial carcinogenesis. Clin Cancer Res 2005;11(18):6512–9. DOI:10.1158/1078-0432.CCR-05-0891; https://oncourology.abvpress.ru/oncur/article/view/1699

Availability: https://oncourology.abvpress.ru/oncur/article/view/1699
https://doi.org/10.17650/1726-9776-2024-20-1-103-108

Comparison of en-bloc resection of the bladder wall and tumor with standard transurethral bladder resection in treatment of non-muscle invasive bladder cancer ; Сравнение en-bloc резекции стенки мочевого пузыря с опухолью со стандартной трансуретральной резекцией мочевого пузыря при лечении немышечно-инвазивного рака мочевого пузыря

Authors: S. V. Kotov, R. I. Guspanov, S. A. Pulbere, A. L. Khachatryan, Sh. M. Sargsian, Yu. P. Kraev, D. A. Samoylov, С. В. Котов, Р. И. Гуспанов, С. А. Пульбере, А. Л. Хачатрян, Ш. М. Саргсян, Ю. П. Краев, Д. А. Самойлов

Source: Cancer Urology; Том 20, № 2 (2024); 101-109 ; Онкоурология; Том 20, № 2 (2024); 101-109 ; 1996-1812 ; 1726-9776

Subject Terms: трансуретральная резекция стенки мочевого пузыря с опухолью, non-muscle-invasive bladder cancer, treatment of non-muscle invasive bladder cancer, transurethral resection of the bladder wall with a tumor, немышечно-инвазивный рак мочевого пузыря, лечение немышечно-инвазивного рака мочевого пузыря

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1824/1537; EAU Guidelines. Edn. presented at the EAU Annual Congress Milan 2023.; Fankhauser C.D., Wettstein M.S., Afferi L. et al. En Bloc Resection of Bladder Tumor-Is It the Way Forward? Front Surg 2021;8:685506. DOI:10.3389/fsurg.2021.685506; Yang H., Lin J., Gao P. et al. Is the en bloc transurethral resection more effective than conventional transurethral resection for nonmuscle-invasive bladder cancer? A systematic review and metaanalysis. Urol Int 2020;104(5–6):402–9. DOI:10.1159/000503734; Mori K., D’Andrea D., Enikeev D.V. et al. En bloc resection for nonmuscle invasive bladder cancer: review of the recent literature. Curr Opin Urol 2020;30(1):41–7. DOI:10.1097/MOU.0000000000000697; Мартов А.Г., Ергаков Д.В., Байков Н.А. Трансуретральная гольмиевая резекция мочевого пузыря с применением техники единого блока. Медицинский вестник Башкортостана 2015;(57).; Котов С.В., Гуспанов Р.И., Хачатрян А.Л. и др. Применение en-bloc резекции стенки мочевого пузыря с опухолью при лечении немышечно-инвазивного рака мочевого пузыря. Онкоурология 2022;18(4):120–8. DOI:10.17650/1726-9776-2022-18-4-120-128; Martin-Doyle W., Leow J.J., Orsola A. et al. Improving selection criteria for early cystectomy in high-grade T1 bladder cancer: a meta-analysis of 15,215 patients. J Clin Oncol 2015;33(6):643–50. DOI:10.1200/JCO.2014.57.6967; Koch M.O., Smith Jr. Natural history and surgical management of superficial bladder cancer (stages Ta/T1/CIS). In: Comprehensive Textbook of Genitourinary Oncology. Chapter 26. Lippincott Williams and Wilkins, Baltimore, 1996. Pp. 405–15.; Rolevich A., Minich A., Nabebina T. et al. Surgeon has a major impact on long-term recurrence risk in patients with nonmuscle invasive bladder cancer. Cent European J Urol 2016;69(2):170–7. DOI:10.5173/ ceju.2016.795; Zhang D., Yao L., Yu S. et al. Safety and efficacy of en bloc transurethral resection versus conventional transurethral resection for primary nonmuscle-invasive bladder cancer: a meta-analysis. World J Surg Oncol 2020;18(1):4. DOI:10.1186/s12957-019-1776-4; Herr H.W., Donat S.M. A restaging transurethral resection predicts early progression of superficial bladder cancer. BJU Int 2006;97:1197–8. DOI:10.1016/S0022-5347(18)33065-9; Woldu S.L., Bagrodia A., Lotan Y. Guideline of guidelines: nonmuscle-invasive bladder cancer. BJU Int 2017;119(3):371–80.; Chen X., Liao J., Chen L. et al. En bloc transurethral resection with 2-micron continuous-wave laser for primary non-muscleinvasive bladder cancer: a randomized controlled trial. World J Urol 2015;33:989–95. DOI:10.1007/s00345-014-1342-1; Sureka S., Agarwal V., Agnihotri S. et al. Is en-bloc transurethral resection of bladder tumor for non-muscle invasive bladder carcinoma better than conventional technique in terms of recurrence and progression? A prospective study. Indian J Urol 2014;30(2):144–9. DOI:10.4103/0970-1591.126887; Kramer M., Altiery V., Hurl R. et al. Current evidence of transurethral en-bloc resection of nonmuscle invasive bladder cancer. Eur Urol Focus 2017;3(6):567–76. DOI:10.1016/j.euf.2016.12.004; https://oncourology.abvpress.ru/oncur/article/view/1824

Availability: https://oncourology.abvpress.ru/oncur/article/view/1824
https://doi.org/10.17650/1726-9776-2024-20-2-101-109

Clinical case of urachal carcinoma treatment ; Клинический случай лечения карциномы урахуса

Authors: N. S. Nurgaliyev, E. A. Ukolova, E. B. Satbaeva, A. A. Aydarkulov, G. T. Rakhimov, Н. С. Нургалиев, Е. А. Уколова, Э. Б. Сатбаева, А. A. Айдаркулов, Г. Т. Рахимов

Source: Cancer Urology; Том 20, № 1 (2024); 140-145 ; Онкоурология; Том 20, № 1 (2024); 140-145 ; 1996-1812 ; 1726-9776

Subject Terms: лечение карциномы урахуса, bladder cancer, chemotherapy of urachal cancer, treatment of urachal carcinoma, рак мочевого пузыря, химиотерапия рака урахуса

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1764/1524; Begg R.C. Theurachus: itsanatomy, histology and development. J Anat 1930;64:170–83.; WHO classification of tumours series. 5th edn. Vol. 8. Available at: https://tumourclassification.iarc.who.int/chapters/36.; Szarvas T., Modos O., Niedworok C. et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma – a comprehensive review with meta-analysis of 1010 cases. Urol Oncol 2016;34:388–98. DOI:10.1016/j.urolonc.2016.04.012; https://www.pathologyoutlines.com/topic/bladderadenourachal.html.; Molina J.R., Quevedo J.F., Furth A.F. et al. Predictors of survival from urachal cancer: a Mayo Clinic study of 49 cases. Cancer 2007;110(11):2434–40. DOI:10.1002/cncr.23070; Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment. Semin Oncol 2012;39(5):619–24. DOI:10.1053/j.seminoncol.2012.08.011; Sheldon C.A., Clayman R.V., Gonzalez R. et al. Malignant urachal lesions. J Urol 1984;131(1):1–8. DOI:10.1016/s0022-5347(17)50167-6; Krysiewicz S. Diagnosis of urachal carcinoma by computed tomography and magnetic resonance imaging. Clin Imaging 1990;14(3):251–4. DOI:10.1016/0899-7071(90)90085-p; Siefker-Radtke A.O., Gee J., Shen Y. et al. Multimodality management of urachal carcinoma: the M.D. Anderson Cancer Center experience. J Urol 2003;169(4):1295–8. DOI:10.1097/01.ju.0000054646.49381.01; Henly D.R., Farrow G.M., Zincke H. Urachal cancer: role of conservative surgery. Urology 1993;42(6):635–9. DOI:10.1016/0090-4295(93)90526-g; Mylonas K.S., O’Malley P., Ziogas I.A. et al. Malignant urachal neoplasms: a population-based study and systematic review of literature. Urol Oncol 2017;35(1):33e11–9. DOI:10.1016/j.urolonc.2016.07.021; Kikuchi M., Kamei S., Morirama Y. et al. Case of urachal cancer treated by neoadjuvant chemotherapywith FOLFOX4 (oxaliplatin, 5-FU and leukovolin). Hinyokika Kiyo 2008;54(8):557–9.; Kume H., Tomita K., Takahashi S., Fukutani K. Irinotecan as a new agent for urachal cancer. Urol Int 2006;76(3):281–2. DOI:10.1159/000091635; Galsky M.D., Iasonos A., Mironov S. et al. Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract. Urology 2007;69:255–9. DOI:10.1016/j.urology.2006.10.029; Jung H.A., Sun J.M., Park S.H. et al. Treatment outcome and relevance of palliative chemotherapy in urachalcancer. Chemotherapy 2014;60(2):73–80. DOI:10.1159/000368071; https://oncourology.abvpress.ru/oncur/article/view/1764

Availability: https://oncourology.abvpress.ru/oncur/article/view/1764
https://doi.org/10.17650/1726-9776-2024-20-1-140-145

Brachytherapy for organ-preserving treatment of bladder cancer ; Брахитерапия при органосохраняющем лечении рака мочевого пузыря

Authors: I. N. Zaborskiy, K. N. Safiullin, E. I. Smolenov, E. O. Shchukina, V. S. Chaykov, A. V. Troyanov, I. O. Dementiev, O. B. Karyakin, S. A. Ivanov, A. D. Kaprin, И. Н. Заборский, К. Н. Сафиуллин, Е. И. Смоленов, Е. О. Щукина, В. С. Чайков, А. В. Троянов, И. О. Дементьев, О. Б. Карякин, С. А. Иванов, А. Д. Каприн

Source: Cancer Urology; Том 20, № 2 (2024); 140-147 ; Онкоурология; Том 20, № 2 (2024); 140-147 ; 1996-1812 ; 1726-9776

Subject Terms: органосохраняющая лучевая терапия, muscle-invasive bladder cancer, radical cystectomy, organ-preserving radiation therapy, мышечно-инвазивный рак мочевого пузыря, радикальная цистэктомия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1823/1543; Barringer B.S. Radium treatment of carcinoma of the bladder. Ann Surg 1921;74(6):751–67.; Orton C.G., Seyedsadr M., Somnay A. Comparison of high and low dose rate remote afterloading for cervix cancer and the importance of fractionation. Int J Radiat Oncol Biol Phys 1991;21(6):1425–34. DOI:10.1016/0360-3016(91)90316-v; Herger C., Sauer H.R. Radium treatment of cancer of bladder. Report of 267 cases. Am J Roentgenol 1942;47:909–15.; Van der Werf-Messing B. Treatment of carcinoma of the bladder with radium. Clin Radiol 1965;16:16–26. DOI:10.1016/s0009-9260(65)80029-0; Van der Werf-Messing B., Star W.M., Menon R.S. T3NXM0 carcinoma of the urinary bladder treated by the combination of radium implant and external irradiation. A preliminary report. Int J Radiat Oncol Biol Phys 1980;6(12):1723–5. DOI:10.1016/0360-3016(80)90259-x; Wijnmaalen A., van der Werf-Messing B.H. Factors influencing the prognosis in bladder cancer. Int J Radiat Oncol Biol Phys 1986;12(4):559–65. DOI:10.1016/0360-3016(86)90063-5; Morson A.C. Observations on twenty-three cases of carcinoma of the bladder treated by radium. Br Med J 1929;1(3570):1038–9. DOI:10.1136/bmj.1.3570.1038; Lenz M., Cahill G.F. The treatment of cancer of the bladder by radium needles. Am J Roentgenol Radium Ther 1947;58(4):486–92.; Barringer B.S. Twenty-five years of radon treatment of cancer of the bladder. J Am Med Assoc 1947;135(10):616–8. DOI:10.1001/jama.1947.02890100010003; Van der Werf-Messing B., Menon R.S., Hop W.C.J. Cancer of the urinary bladder category T2, T3, (NXM0) treated by interstitial radium implant: second report. Int J Radiat Oncol Biol Phys 1983;9(4):481–5. DOI:10.1016/0360-3016(83)90064-0; Van der Werf-Messing B.H., Van Putten W.L. Carcinoma of the urinary bladder category T2,3NXM0 treated by 40 Gy external irradiation followed by cesium137 implant at reduced dose (50 %). Int J Radiat Oncol Biol Phys 1989;16(2):369–71. DOI:10.1016/0360-3016(89)90332-5; Mazeron J.J., Crook J., Chopin D. et al. Conservative treatment of bladder carcinoma by partial cystectomy and interstitial iridium 192. Int J Radiat Oncol Biol Phys 1988;15(6):1323–30. DOI:10.1016/0360-3016(88)90227-1; De Neve W., Lybeert M.L., Goor C. et al. T1 and T2 carcinoma of the urinary bladder: Long term result with external, preoperative, or interstitial radiotherapy. Int J Radiat Oncol Biol Phys 1992;23(2):299–304. DOI:10.1016/0360-3016(92)90745-4; Battermann J.J., Tierie A.H. Results of implantation for T1 and T2 bladder tumours. Radiother Oncol 1986;5(2):85–90. DOI:10.1016/s0167-8140(86)80161-x; Pernot M., Hubert J., Guillemin F. et al. Combined surgery and brachytherapy in the treatment of some cancers of the bladder (partial cystectomy and interstitial iridium-192). Radiother Oncol 1996;38(2):115–20. DOI:10.1016/0167-8140(96)82354-1; Wijnmaalen A., Helle P.A., Koper P.C. et al. Muscle invasive bladder cancer treated by transurethral resection, followed by external beam radiation and interstitial iridium-192. Int J Radiat Oncol Biol Phys 1997;39(5):1043–52. DOI:10.1016/s0360-3016(97)00375-1; De Crevoisier R., Ammor A., Court B. et al. Bladder-conserving surgery and interstitial brachytherapy for lymph node negative transitional cell carcinoma of the urinary bladder: Results of a 28-year single institution experience. Radiother Oncol 2004;72(2):147–57. DOI:10.1016/j.radonc.2004.06.002; Nieuwenhuijzen J.A., Pos F., Moonen L.M.F. et al. Survival after bladder-preservation with brachytherapy versus radical cystectomy; a single institution experience. Eur Urol 2005;48(2):239–45. DOI:10.1016/j.eururo.2005.03.022; Rozan R., Albuisson E., Donnarieix D. et al. Interstitial iridium-192 for bladder cancer (A multicentric survey: 205 patients). Int J Radiat Oncol Biol Phys 1992;24(3):469–77. DOI:10.1016/0360-3016(92)91061-q; Brenner D.J., Hall E.J. Conditions for the equivalence of continuous to pulsed low dose rate brachytherapy. Int J Radiat Oncol Biol Phys 1991;20(1):181–90. DOI:10.1016/0360-3016(91)90158-z; Soete G., Coen V., Verellen D. et al. A feasibility study of high dose rate brachytherapy in solitary urinary bladder cancer. Int J Radiat Oncol Biol Phys 1997;38(4):743–7. DOI:10.1016/s0360-3016(97)00063-1; Pos F.J., Horenblas S., Lebesque J. et al. Low-dose-rate brachytherapy is superior to high-dose-rate brachytherapy for bladder cancer. Int J Radiat Oncol Biol Phys 2004;59(3):696–705. DOI:10.1016/j.ijrobp.2003.11.040; Blank L.E.C.M., Koedooder K., van Os R. et al. Results of bladderconserving treatment, consisting of brachytherapy combined with limited surgery and external beam radiotherapy, for patients with solitary T1-T3 bladder tumors less than 5 cm in diameter. Int J Radiat Oncol Biol Phys 2007;69(2):454–8. DOI:10.1016/j.ijrobp.2007.03.014; Koning C.C.E.,Blank L.E.C.M., Koedooder C. et al. Brachytherapy after external beam radiotherapy and limited surgery preserves bladders for patients with solitary pT1-pT3 bladder tumors. Ann Oncol 2012;23(11):2948–53. DOI:10.1093/annonc/mds126; Smits G.A.H.J., Van der Steen-Banasik E., Oosterveld B. et al. Minimal invasive surgery and brachytherapy as bladder preserving multimodality treatment in selected solitary MIBC. Eur Urol Suppl 2019;18(1):e814. DOI:10.1016/S1569-9056(19)30594-9; Van der Steen-Banasik E.M., Smits G.A.H.J., Oosterveld B.J. et al. The Curie-Da Vinci connection: 5-years’ experience with laparoscopic (robot-assisted) implantation for high-dose-rate brachytherapy of solitary T2 bladder tumors. Int J Radiat Oncol Biol Phys 2016;95(5):1439–42. DOI:10.1016/j.ijrobp.2016.03.029; Bus S.J.E.A., Leus N.G., Oosterveld B.J. et al. An evaluation of our experience in position verification of catheters used for interstitial high-dose-rate brachytherapy of solitary bladder tumors. Brachytherapy 2018;17(1):24–30. DOI:10.1016/j.brachy.2017.01.013; Voskuilen C.S., Bosschieter J., van Werkhoven E. et al. Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiother Oncol 2019;141:130–6. DOI:10.1016/j.radonc.2019.09.026; Van Onna I.E.W., Oddens J.R., Kok E.T. et al. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients. Eur Urol 2009;56(1):113–22. DOI:10.1016/j.eururo.2008.07.043; Van der Steen-Banasik E., Ploeg M., Witjes J.A. et al. Brachytherapy versus cystectomy in solitary bladder cancer: A case control, multicentre, East-Netherlands study. Radiother Oncol 2009;93(2):352–357. DOI:10.1016/j.radonc.2009.04.020; Aluwini S., Van Rooij P.H.E., Kirkels W.J. et al. Bladder function preservation with brachytherapy, external beam radiation therapy, and limited surger in bladder cancer patients: Long-term results. Int J Radiat Oncol Biol Phys 2014;88(3):611–7. DOI:10.1016/j.ijrobp.2013.11.227; Krasnow R.E., Drumm M., Roberts H.J. et al. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol 2017;72(1):54–60. DOI:10.1016/j.eururo.2016.12.002; Han B., Liang S., Jing Y. et al. Organ preservation for muscleinvasive bladder cancer by preoperative intra-arterial chemotherapy and transurethral resection. Med Oncol 2014;31(4):912. DOI:10.1007/s12032-014-0912-9; Mak R.H., Hunt D., Shipley W.U. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014;32(34):3801–9. DOI:10.1200/JCO.2014.57.5548; Pieters B.R., Van der Steen-Banasik E., Smits G.A. et al. GEC-ESTRO/ACROP recommendations for performing bladdersparing treatment with brachytherapy for muscle-invasive bladder carcinoma. Radiother Oncol 2017;122(3):340–6. DOI:10.1016/j.radonc.2016.12.022; Richtlijn Blaascarcinoom Nederlandstalige samenvatting van de EAU guidelines on bladder cancer. Available at: http://www.nvu.nl; https://oncourology.abvpress.ru/oncur/article/view/1823

Availability: https://oncourology.abvpress.ru/oncur/article/view/1823
https://doi.org/10.17650/1726-9776-2024-20-2-140-147

Ureteroileal anastomosis-associated complications of radical cystectomy with ileal conduit in bladder cancer treatment ; Осложнения радикальной цистэктомии с кишечной деривацией мочи при раке мочевого пузыря, ассоциированные с уретероилеальными анастомозами

Authors: D. I. Rumiantseva, E. M. Mamizhev, N. F. Krotov, N. А. Shchekuteev, M. E. Karasev, D. P. Semeyko, Ya. P. Bashmakova, A. K Nosov, Д. И. Румянцева, Э. М. Мамижев, Н. Ф. Кротов, Н. А. Щекутеев, М. Е. Карасева, Д. П. Семейко, Я. П. Башмакова, А. К. Носов

Source: Cancer Urology; Том 20, № 3 (2024); 104-116 ; Онкоурология; Том 20, № 3 (2024); 104-116 ; 1996-1812 ; 1726-9776

Subject Terms: несостоятельность, bladder cancer, stricture, urinary incontinence, рак мочевого пузыря, стриктура

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1813/1560; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1508; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1509; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1510; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1511; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1512; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1813/1513; Compérat E., Larré S., Roupret M. et al. Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old. Virchows Arch 2015;466(5):589–94. DOI:10.1007/s00428-015-1739-2; Cheng Q., Gu L., Zhao X. et al. A new index (A/G) associated with early complications of radical cystectomy and intestinal urinary diversion. Urol Oncol 2021;39(5):301.e11–6. DOI:10.1016/j.urolonc.2020.09.023; Stenzl A., Sherif H., Kuczyk M. Radical cystectomy with orthotopic neobladder for invasive bladder cancer: a critical analysis of long term oncological, functional and quality of life results. Int Braz J Urol 2010;36(5):537–47. DOI:10.1590/s1677-55382010000500003; Vallancien G., El Fettouh H.A., Cathelineau X. et al. Cystectomy with prostate sparing for bladder cancer in 100 patients: 10-year experience. J Urol 2002;168(6):2413–7. DOI:10.1016/S0022-5347(05)64157-2; Hautmann R.E., Volkmer B.G., Schumacher M.C. et al. Long-term results of standard procedures in urology: the ileal neobladder. World J Urol 2006;24(3):305–14. DOI:10.1007/s00345-006-0105-z.; Hautmann R.E., de Petriconi R.C., Volkmer B.G. 25 years of experience with 1,000 neobladders: long-term complications. J Urol 2011;185(6):2207–12. DOI:10.1016/j.juro.2011.02.006; Tanna R.J., Powell J., Mambu L.A. Ileal Conduit. In: StatPearls [Internet]. 2022. Treasure Island (FL): StatPearls Publishing, 2024. PMID: 33351418.; Wang J., Tuo Z., Gao M. et al. Is it necessary to perform a retrosigmoid transposition of the left ureter in Bricker Ileal Conduit surgery? BMC Urol 2022;22(1):116. DOI:10.1186/s12894-022-01073-w; Adnan S., Abu Bakar M., Khalil M.A.I. et al. Outcomes of uretero-ileal anastomosis in bladder cancer cystectomies: Bricker vs. Wallace 1. Cureus 2022;14(3):e22782. DOI:10.7759/cureus.22782; Korkes F., Fernandes E., Gushiken F.A. et al. Bricker ileal conduit vs. Cutaneous ureterostomy after radical cystectomy for bladder cancer: a systematic review. Int Braz J Urol 2022;48(1):18–30. DOI:10.1590/S1677-5538.IBJU.2020.0892; Kouba E., Sands M., Lentz A. et al. Incidence and risk factors of stomal complications in patients undergoing cystectomy with ileal conduit urinary diversion for bladder cancer. J Urol 2007; 178(3 Pt 1):950–4. DOI:10.1016/j.juro.2007.05.028; Bricker E.M. Bladder substitution after pelvic evisceration. Surg Clin North Am 1950;30(5):1511–21. DOI:10.1016/s0039-6109(16)33147-4; Gore J.L., Saigal C.S., Hanley J.M. et al. Variations in reconstruction after radical cystectomy. Cancer 2006;107(4): 729–7. DOI:10.1002/cncr.22058; Madersbacher S., Schmidt J., Eberle J.M. et al. Long-term outcome of ileal conduit diversion. J Urol 2003;169(3):985–90. DOI:10.1097/01.ju.0000051462.45388.14; Scott F.B., Cookson M.S. Surgical complications of urinary diversion. World J Urol 2004;22(3):157–67. DOI:10.1007/s00345-004-0429-5; Shimko M.S., Tollefson M.K., Umbreit E.C. et al. Long-term complications of conduit urinary diversion. J Urol 2011;185(2): 562–7. DOI:10.1016/j.juro.2010.09.096; Witjes J.A., Bruins H.M., Cathomas R. et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol 2021;79(1): 82–104. DOI:10.1016/j.eururo.2020.03.055; Djaladat H., Bruins H.M., Miranda G. et al. The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer. BJU Int 2014;113(6):887–93. DOI:10.1111/bju.12240; Chang S.S., Alberts G.L., Smith J.A. Jr, Cookson M.S. Ileal conduit urinary diversion in patients with previous history of abdominal/ pelvic irradiation. World J Urol 2004;22(4):272–6. DOI:10.1007/s00345-004-0446-4; Partin A.W., Wein A.J., Kavoussi L.R. et al. Campbell Walsh Wein Urology. Elsevier Health Sciences, 12th edn. 2020.; Regan J.B., Barrett D.M. Stented versus nonstented ureteroileal anastomoses: is there a difference with regard to leak and stricture? J Urol 1985;134(6):1101–3. DOI:10.1016/s0022-5347(17)47644-0; Beddoe A.M., Boyce J.G., Remy J.C. et al. Stented versus nonstented transverse colon conduits: a comparative report. Gynecol Oncol 1987;27(3):305–15. DOI:10.1016/0090-8258(87)90250-2; Yanagisawa T., Mori K., Quhal F. et al. Iatrogenic ureteric injury during abdominal or pelvic surgery: a meta-analysis. BJU Int 2023;131(5):540–52. DOI:10.1111/bju.15913; Stein R., Fisch M., Stöckle M. et al. Colonic conduit in children: protection of the upper urinary tract 16 years later? J Urol 1996;156(3):1146–50. DOI:10.1016/s0022-5347(01)65739-2; Dolezel J., Sutorý M., Navrátil P. Antireflux uretero-intestinal anastomosis – flap-and-trough technique – applicable to ileum: early clinical experience. Eur Urol 2004;46(5):598–603. DOI:10.1016/j.eururo.2004.06.018; https://oncourology.abvpress.ru/oncur/article/view/1813

Availability: https://oncourology.abvpress.ru/oncur/article/view/1813
https://doi.org/10.17650/1726-9776-2024-20-3-104-116

Парціальна цистектомія з ад’ювантною хіміо- або променевою терапією при м’язово-інвазивному раку сечового міхура (огляд літератури)

Authors: Navrotskyi, B.M.

Source: Practical oncology; Том 2, № 4 (2019); 40-44
Практическая онкология-Praktična onkologìâ; Том 2, № 4 (2019); 40-44
Практична онкологія-Praktična onkologìâ; Том 2, № 4 (2019); 40-44

Subject Terms: тримодальна терапія раку сечового міхура, м'язово-інвазивний рак сечового міхура, парціальна цистектомія, радикальна цистектомія, трехмодальная терапия рака мочевого пузыря, мышечно-инвазивный рак мочевого пузыря, парциальная цистэктомия, радикальная цистэктомия, trimodal bladder cancer therapy, muscle invasive bladder cancer, partial cystectomy, radical cystectomy, 3. Good health

File Description: application/pdf

Access URL: http://oncology.zaslavsky.com.ua/article/download/195185/197116
http://oncology.zaslavsky.com.ua/article/view/195185

Electromyographic features of the perineum and pelvic floor in patients with an artificial bladder

Authors: R.V. Savchuk, F.I. Kostyev, S.V. Golovko, Y.M. Dekhtiar, K.A. Zalyva

Source: Medičnì Perspektivi, Vol 26, Iss 3 (2021)
Медичні перспективи; Том 26 № 3 (2021); 33-39
Medicni perspektivi (Medical perspectives); Vol. 26 No. 3 (2021); 33-39

Subject Terms: artificial bladder, електроміографія, рак мочевого пузыря, electromyographic, артифіційний сечовий міхур, тазовое дно, perineum, промежность, артифициальный мочевой пузырь, электромиография, 3. Good health, 03 medical and health sciences, рак сечового міхура, 0302 clinical medicine, pelvic floor, тазове дно, bladder cancer, Medicine, промежина

File Description: application/pdf

Access URL: http://journals.uran.ua/index.php/2307-0404/article/download/241930/240392
https://doaj.org/article/9e17b13dc1b84843a9bd172875e1dd2f
https://cyberleninka.ru/article/n/electromyographic-features-of-the-perineum-and-pelvic-floor-in-patients-with-an-artificial-bladder
http://journals.uran.ua/index.php/2307-0404/article/view/241930

Эффективность и выбор лекарственной терапии местнораспространенного или метастатического рака мочевого пузыря при сопутствующей хронической болезни почек II-IV ст

Subject Terms: anti-tumor antibodies, местнораспространенный или метастатический рак мочевого пузыря, противоопухолевые антитела, CKD, ХБП, экспрессия PD-L1, PD-L1 expression, locally advanced or metastatic bladder cancer, monotherapy with gemcitabine, монотерапия гемцитабином

КЛИНИЧЕСКИЙ СЛУЧАЙ АГРЕССИВНОЙ ФОРМЫ РАКА МОЧЕВОГО ПУЗЫРЯ С РАСПРОСТРАНЕННЫМ МЕТАСТАЗИРОВАНИЕМ

Subject Terms: профилактика, рак мочевого пузыря, diagnosis, prevention, диагностика, bladder cancer, metastasis, метастазирование, UBC-тест, UBC test

ЭМБОЛИЗАЦИЯ ИСТОЧНИКА КРОВОТЕЧЕНИЯ У ПАЦИЕНТА С АТИПИЧНОЙ АНАТОМИЕЙ ВПЕРВЫЕ ВЫЯВЛЕННОГО НОВООБРАЗОВАНИЯ МАЛОГО ТАЗА В ОСТРОМ ПЕРИОДЕ ИНФАРКТА МИОКАРДА (КЛИНИЧЕСКОЕ НАБЛЮДЕНИЕ)

Subject Terms: STEMI, кровотечение, endovascular embolization, рак мочевого пузыря, эндоваскулярный гемостаз, bladder cancer, эндоваскулярная эмболизация, endovascular hemostasis, bleeding, prostate cancer, рак предстательной железы, 3. Good health

Volumetric tumor segmentation according to diffusion-weighted MRI data in predicting and evaluating the response to chemotherapy in bladder cancer ; Возможности объемной сегментации опухоли по данным диффузионно-взвешенной МРТ в прогнозировании и оценке эффективности химиотерапии при раке мочевого пузыря

Authors: E. G. Grigoriev, I. G. Frolova, E. A. Usynin, A. V. Usova, S. A. Tabakaev, Е. Г. Григорьев, И. Г. Фролова, Е. А. Усынин, А. В. Усова, С. А. Табакаев

Source: Siberian journal of oncology; Том 22, № 3 (2023); 25-35 ; Сибирский онкологический журнал; Том 22, № 3 (2023); 25-35 ; 2312-3168 ; 1814-4861

Subject Terms: оценка эффективности химиотерапии, diffusion-weighted images, bladder tumor, prognosis, efficacy evaluation of chemotherapy, диффузионно-взвешенные изображения, рак мочевого пузыря, прогнозирование

File Description: application/pdf

Relation: https://www.siboncoj.ru/jour/article/view/2601/1127; Каприн А.Д., Старинский В.В., Петровой Г.В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). М., 2019. 250 с.; Babjuk M., Burger M., Comperat E., Gontero P., Mostafid A., Palou J. EAU Guidelines. Edn. presented at the EAU Annual Congress Amsterdam, 2020.; Down C.J., Nair R., Thurairaja R. Bladder cancer. Surgery (Oxford). 2016; 34(10): 532-9. doi:10.1016/j.mpsur.2016.08.001.; Григорьев Е.Г., Фролова И.Г., Усынин Е.А., Величко С.А., Окунев В.В., Гольдберг А.В. Рак мочевого пузыря: возможности высокопольной магнитно-резонансной томографии (обзор литературы). Сибирский онкологический журнал. 2014; (3): 65-71.; Bostrom P.J., van Rhijn B.W., Fleshner N., Finelli A., Jewett M., Thoms J., Hanna S., Kuk C., Zlotta A.R. Staging and staging errors in bladder cancer. Eur Urol Suppl. 2010; 9(1): 2-9. doi:10.1016/j.eursup.2010.01.005.; Фролова И.Г., Григорьев Е.Г., Величко СА., Усова А.В., Трухачева Н.Г. Диффузионно-взвешенная магнитно-резонансная томография в диагностике и стадировании рака мочевого пузыря. Вестник рентгенологии и радиологии. 2019; 100(6): 379-86. doi:10.20862/0042-4676-2019-100-6-379-386.; Panebianco V., Pecoraro M., Del Giudice F., Takeuchi M., Muglia V.F., Messina E., Cipollari S., Giannarini G., Catalano C., Narumi Y. VI-RADS for Bladder Cancer: Current Applications and Future Developments. J Magn Reson Imaging. 2022; 55(1): 23-36. doi:10.1002/jmri.27361.; Harri P.A., Alexander L., Camacho J.C., Moreno C.C., Mittal P. Magnetic Resonance Imaging Evaluation of Urothelial Cell Carcinoma: Histopathological Correlation, Staging, and Treatment Planning. Curr Prob Diagn Radiol. 2018; 47(1): 28-41. doi:10.1067/j.cpradiol.2017.04.009.; Barsoum N., Talaat M., Saraya S. Can diffusion-weighted MRI predict the histological grade of urinary bladder carcinoma? Kasr Al Ainy Medical Journal. 2017; 23(2): 86-95. doi:10.4103/kamj.kamj_53_16.; Yoshida S., Koga F., Kobayashi S., Ishii C., Tanaka H., Tanaka H., Komai Yo., Saito K., Masuda H., Ya. Fujii, Kawakami S., Kihara K. Role of diffusion-weighted magnetic resonance imaging in predicting sensitivity to chemoradiotherapy in muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 2012; 83(1): 21-7. doi:10.1016/j.ijrobp.2011.11.065.; Kobayashi S., Koga F., Kajino K., Yoshita S., Ishii C., Tanaka H., Saito K., Masuda H., Fujii Y., Yamada T., Kihara K. Apparent diffusion coefficient value reflects invasive and proliferative potential of bladder cancer. J Magn Reson Imaging. 2014; 39(1): 172-8. doi:10.1002/jmri.24148.; van Persijn, van Meerten E.L., Gelderblom H., Bloem J.L. RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline. Eur Radiol. 2010; 20(6): 1456-67. doi:10.1007/s00330-009-1685-y.; https://www.siboncoj.ru/jour/article/view/2601

Availability: https://www.siboncoj.ru/jour/article/view/2601
https://doi.org/10.21294/1814-4861-2023-22-3-25-35

Laparoscopic extraperitoneal radical cystoprostatectomy: for whom and how? ; Лапароскопическая экстраперитонеальная радикальная цистпростатэктомия: кому и как?

Authors: D. V. Perlin, I. V. Aleksandrov, A. O. Shmanev, Sh. Shamhalov, P. A. Kulikov, Д. В. Перлин, И. В. Александров, А. О. Шманев, Ш. Шамхалов, П. А. Куликов

Source: Cancer Urology; Том 19, № 3 (2023); 69-78 ; Онкоурология; Том 19, № 3 (2023); 69-78 ; 1996-1812 ; 1726-9776

Subject Terms: спасительная цистэктомия, extraperitoneal access, muscle-invasive bladder cancer, salvage cystectomy, экстраперитонеальный доступ, инвазивный рак мочевого пузыря

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1680/1481; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1254; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1255; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1256; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1257; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1260; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1261; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1680/1262; Martini T., Mayr R., Wehrberger C. et al. Comparison of radical cystectomy with conservative treatment in geriatric (≥80) patients with muscle-invasive bladder cancer. Int Braz J Urol 2013;39(5):622–30. DOI:10.1590/S1677-5538.IBJU.2013.05.03; Zeng S., Zhang Z., Yu X. et al. Laparoscopic versus open radical cystectomy for elderly patients over 75-year-old: a single center comparative analysis. PLoS One 2014;9:e98950. DOI:10.1371/journal.pone.0098950; Fontana P.P., Gregorio S.A., Rivas J.G. et al. Perioperative and survival outcomes of laparoscopic radical cystectomy for bladder cancer in patients over 70 years. Cent European J Urol 2015;68(1):24–9. DOI:10.5173/ceju.2015.01.498; Richards K.A., Kader A.K., Otto R. et al. Is robot-assisted radical cystectomy justifid in the elderly? A comparison of robotic versus open radical cystectomy for bladder cancer in elderly ≥75 years old. J Endourol 2012;26(10):1301–6. DOI:10.1089/end.2012.0035; Brodak M., Tomasek J., Pacovsky J. et al. Urological surgery in elderly patients: results and complications. Clin Interv Aging 2015;10:379–84. DOI:10.2147/CIA.S73381; Feng L., Song J., Wu M. et al. Extraperitoneal versus transperitoneal laparoscopic radical cystectomy for selected elderly bladder cancer patients: asingle center experience. Int braz J Urol 2016;42(4):655–62. DOI:10.1590/S1677-5538.IBJU.2015.0608; Serel T.A., Sevin G., Perk H. et al. Antegrade extraperitoneal approach to radical cystectomy and ileal neobladder. Int J Urol 2003;10(1):25–8. DOI:10.1046/j.1442-2042.2003.00560.x; Zhao J., Zeng S., Zhang Z. et al. Laparoscopic radical cystectomy versus extraperitoneal radical cystectomy: is the extraperitoneal technique rewarding? Clin Genitourin Cancer 2015;13(4):e271–7. DOI:10.1016/j.clgc.2015.01.006; Roth B., Birkhäuser F.D., Zehnder P. et al. Readaptation of the peritoneum following extended pelvic lymphadenectomy and cystectomy has a signifiant benefiial impact on early postoperative recovery and complications: results of a prospective randomized trial. Eur Urol 2011;59(2):204–10. DOI:10.1016/j.eururo.2010.10.030; Kulkarni J.N., Gulla R.I., Tongaonkar H.B. et al. Radical cystoprostatectomy: an extraperitoneal retrograde approach. J Urol 1999;161(2):545–8. DOI:10.1016/s0022-5347(01)61946-3; Verze P., Scuzzarella S., Martina G.R. et al. Long-term oncological and functional results of extraperitoneal laparoscopic radical prostatectomy: one surgical team’s experience on 1,600 consecutive cases. World J Urol 2013;31(3):529–34. DOI:10.1007/s00345-013-1052-0; Lei Y., Tong S., Zu X. et al. Extraperitoneal and transperitoneal laparoscopic partial cystectomy for benign non-urothelial bladder tumors: an initial experience. Urol Int 2015;94(2):149–55. DOI:10.1159/000366067; Zhu Y.P., Ye D.W., Yao X.D. et al. Defiing good candidates for extraperitoneal cystectomy: results from random peritoneum biopsies of 136 cases. Urology 2013;81(4):820–4. DOI:10.1016/j.urology.2012.11.057; Pakish D., Soliman P., Frumovitz M. et al. A comparison extraperitoneal versus transperitoneal laparoscopic para-aortic lymphadenectomy for staging endometrial carcinoma. Ginecol Oncol 2014;132(2):366–71. DOI:10.1016/j.ygyno.2013.12.019; Jensen J.B., Ulhøi B.P., Jensen K.M. Extended versus limited lymph node dissection in radical cystectomy: impact on recurrence pattern and survival. Int J Urol 2012;19(1):39–47. DOI:10.1111/j.1442-2042.2011.02887.x; Bi L., Huang H., Fan X. et al. Extended vs non-extended pelvic lymph node dissection and their inflence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies. BJU Int 2014;113(5b):E39–48. DOI:10.1111/bju.12371; Larcher A., Sun M., Schiffmann J. et al. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. Eur J Surg Oncol 2015;41(3):353–60. DOI:10.1016/j.ejso.2014.10.061; Vakalopoulos I., Dimitriadis G., Anastasiadis A. et al. Does intubated uretero-ureterocutaneostomy provide better health-related quality of life than orthotopic neobladder in patients after radical cystectomy for invasive bladder cancer? Int Urol Nephrol 2011;43(3): 743–8. DOI:10.1007/s11255-011-9904-2; https://oncourology.abvpress.ru/oncur/article/view/1680

Availability: https://oncourology.abvpress.ru/oncur/article/view/1680
https://doi.org/10.17650/1726-9776-2023-19-3-69-78

Biomarkers determining treatment tactics in metastatic urothelial cancer ; Биомаркеры, определяющие лечебную тактику при метастатическом уротелиальном раке

Authors: L. Yu. Grivtsova, O. B. Karyakin, M. G. Syadrin, S. M. Samborsky, S. A. Ivanov, A. D. Kaprin, Л. Ю. Гривцова, О. Б. Карякин, М. Г. Сядрин, С. М. Самборский, С. А. Иванов, А. Д. Каприн

Source: Cancer Urology; Том 19, № 2 (2023); 111-126 ; Онкоурология; Том 19, № 2 (2023); 111-126 ; 1996-1812 ; 1726-9776

Subject Terms: таргетная терапия, muscle-invasive bladder cancer, biomarker, chemotherapy, biotherapy, immunotherapy, targeted therapy, мышечно-инвазивный рак мочевого пузыря, биомаркер, химиотерапия, биотерапия, иммунотерапия

File Description: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1676/1464; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/1676/1253; Bellmunt J., Théodore C., Demkov T. et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009;27(27):4454–61. DOI:10.1200/JCO.2008.20.5534; McCaffrey J.A., Hilton S., Mazumdar M. et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997;15(5):1853–7. DOI:10.1200/JCO.1997.15.5.1853; Szklener K., Chmiel P., Michalski A., Mańdziuk S. New directions and challenges in targeted therapies of advanced bladder cancer: the role of FGFR inhibitors. Cancers 2022;14(6):1416. DOI:10.3390/cancers14061416; Khalife N., Chahine C., Kordahi M. et al. Urothelial carcinoma in the era of immune checkpoint inhibitors. Immunotherapy 2021;13(11):953–64. DOI:10.2217/imt-2021-0042; Heath E.I., Rosenberg J.E. The biology and rationale of targeting nectin–4 in urothelial carcinoma. Nat Rev Urol 2021;18(2):93–103. DOI:10.1038/s41585-020-00394-5; Tagawa S.T., Balar A.V., Petrylak D.P. et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinumbased chemotherapy and checkpoint inhibitors abstract. J Clin Oncol 2021;39(22):2474–85. DOI:10.1200/JCO.20.03489; Powles T., Park S.H., Voog E. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383(13):1218–30. DOI:10.1056/NEJMoa2002788; Bellmunt J., de Wit R., Vaughn D.J. et al. KEYNOTE-045 Investigators. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376(11):1015–26. DOI:10.1056/NEJMoa1613683; Powles T., Rosenberg J.E., Sonpavde G.P. et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384(12):1125–35. DOI:10.1056/NEJMoa2035807; Loriot Y., Balar A., Petrylak D. et al. LBA24 TROPHY-U-01 cohort 1 final results: a phase II study of sacituzumab govitecan (SG) in metastatic urothelial cancer (mUC) that has progressed after platinum (PLT) and checkpoint inhibitors (CPI). Ann Oncol 2020;31:1142–215.; Loriot Y., Necchi A., Park S.H. et al. BLC2001 Study Group. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381(4):338–48. DOI:10.1056/NEJMoa1817323; Loehrer Sr P.J., Einhorn L.H., Elson P.J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate,vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10(7):1066–73. DOI:10.1200/JCO.1992.10.7.1066; Logothetis C.J., Dexeus F.H., Finn L. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol 1990;8(6):1050–5. DOI:10.1200/JCO.1990.8.6.1050; Von der Maase H., Hansen S.W., Roberts J.T. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068–77. DOI:10.1200/JCO.2000.18.17.3068; Galsky M.D., Arija J.Á.A., Bamias A. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2020;395(10236):1547–57. DOI:10.1016/S0140-6736(20)30230-0; Powles T., Csőszi T., Özgüroğlu M. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol 2021;22(7):931–45. DOI:10.1016/S1470-2045(21)00152-2; Powles T., van der Heijden M.S., Castellano D. et al. Durvalumab alone and durvalumab plus tremelimumab versus hemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, openlabel, multicentre, phase 3 trial. Lancet Oncol 2020;21(12):1574–88. DOI:10.1016/S1470-2045(20)30541-6; Rosenberg J.E., Flaig T.W., Friedlander T.W. et al. Study EV-103: durability results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2020;38:5044 (2021;39(15):4528).; Li X., Heyer W.D. Homologous recombination in DNA repair and DNA damage tolerance. Cell Res 2008;18(1):99–113. DOI:10.1038/cr.2008.1; Reardon J.T., Vaisman A., Chaney S.G., Sancar A. Efficient nucleotide excision repair of cisplatin, oxaliplatin, and bis-acetoammine-dichloro-cyclohexylamine-platinum(IV) (JM216) platinum intrastrand DNA diadducts. Cancer Res 1999;59(16):3968–71.; Lord R.V.N., Brabender J., Gandara D. et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002;8(7):2286–91.; Britten R.A., Liu D., Tessier A. et al. ERCC1 expression as a molecular marker of cisplatin resistance in human cervical tumor cells. Int J Cancer 2000;89(5):453–7.; Olaussen K.A., Dunant A., Fouret P. et al. IALT Bio Investigators. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatinbased adjuvant chemotherapy. N Engl J Med 2006;355(10):983–91. DOI:10.1056/NEJMoa060570; Dabholkar M., Vionnet J., Bostick-Bruton F. et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994;94(2):703–8. DOI:10.1172/JCI117388; Metzger R., Leichman C.G., Danenberg K.D. et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16(1):309–16. DOI:10.1200/JCO.1998.16.1.309; Shirota Y., Stoehlmacher J., Brabender J. et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001;19(23):4298–304. DOI:10.1200/JCO.2001.19.23.4298; Klatte T., Seitz C., Rink M. et al. ERCC1 as a prognostic and predictive biomarker for urothelial carcinoma of the bladder following radical cystectomy. J Urol 2015;194(5):1456–62. DOI:10.1016/j.juro.2015.06.099; Necchi A., Lo Vullo S., Raggi D. et al. Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: an open-label, single-arm, single-center, phase 2 study. Urol Oncol 2018;36(1):8.e1–8. DOI:10.1016/j.urolonc.2017.08.020; Hemdan T., Segersten U., Malmström P. 122 ERCC1-negative tumors benefit from neoadjuvant cisplatin-based chemotherapy whereas patients with ERCC1-positive tumors do not – results from a cystectomy trial database. Eur Urol 2014;13(1):e122.; Choueiri T.K., Jacobus S., Bellmunt J. et al. Neoadjuvant dosedense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J Clin Oncol 2014;32(18):1889–94. DOI:10.1200/JCO.2013.52.4785; Sakano S., Ogawa S., Yamamoto Y. et al. ERCC1 and XRCC1 expression predicts survival in bladder cancer patients receiving combined trimodality therapy. Mol Clin Oncol 2013;1(3):403–10. DOI:10.3892/mco.2013.85; Sun J.M., Sung J.Y., Park S.H. et al. ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy. BMC Cancer 2012;12:187. DOI:10.1186/1471-2407-12-187; Kawashima A., Takayama H., Kawamura N. et al. Co-expression of ERCC1 and Snail is a prognostic but not predictive factor of cisplatin-based neoadjuvant chemotherapy for bladder cancer. Oncol Lett 2012;4(1):15–21. DOI:10.3892/ol.2012.689; Ozcan M.F., Dizdar O., Dincer N. et al. Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum–based neoadjuvant chemotherapy. Urol Oncol 2013;31(8):1709–15. DOI:10.1016/j.urolonc.2012.06.014; Nikitas N., Karadimou A., Tsitoura E. et al. Association of ERCC1 SNPs with outcome in platinum–treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study. Pharmacogenomics 2012;13(14):1595–607. DOI:10.2217/pgs.12.162; Kim K.H., Do I.G., Kim H.S. et al. Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin–based chemotherapy. APMIS 2010;118(12):941–8. DOI:10.1111/j.1600-0463.2010.02648.x; Hoffmann A.C., Wild P., Leicht C. et al. MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy. Neoplasia 2010;12(8):628–36. DOI:10.1593/neo.10402; Bellmunt J., Paz-Ares L., Cuello M. et al. Spanish Oncology Genitourinary Group. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007;18(3):522–8. DOI:10.1093/annonc/mdl435; Urun Y., Leow J.J., Fay A.P. et al. ERCC1 as a prognostic factor for survival in patients with advanced urothelial cancer treated with platinum based chemotherapy: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2017;120:120–6. DOI:10.1016/j.critrevonc.2017.10.012; Li Q., Damish A.W., Frazier Z. et al. ERCC2 helicase domain mutations confer nucleotide excision repair deficiency and drive cisplatin sensitivity in muscle–invasive bladder cancer. Clin Cancer Res 2019;25(3):977–88. DOI:10.1158/1078-0432.CCR-18-1001; Van Allen E.M., Mouw K.W., Kim P. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov 2014;4(10):1140–53. DOI:10.1158/2159-8290.CD-14-0623; Liu D., Plimack E.R., Hoffman-Censits J. et al. Clinical validation of chemotherapy response biomarker ERCC2 in muscle-invasive urothelial bladder carcinoma. JAMA Oncol 2016;2(8):1094–6. DOI:10.1001/jamaoncol.2016.1056; Christensen E., Birkenkamp-Demtröder K., Sethi H. et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 2019;37(18):1547–57. DOI:10.1200/JCO.18.02052; Groenendijk F.H., de Jong J., Fransen van de Putte E.E. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2016;69(3):384–8. DOI:10.1016/j.eururo.2015.01.014; Groenendijk F.H., Fransen van de Putte E.E., van Rhijn B.W. et al. Garraway and Jonathan E. Rosenberg’s Letter to the Editor re: Groenendijk F.H., de Jong J., Fransen van de Putte E.E. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur Urol 2015;68(2):e33–4.; Taber A., Christensen E., Lamy P. et al. Molecular correlates of cisplatin-based chemotherapy response in muscle invasive bladder cancer by integrated multiomics analysis. Nat Commun 2020;11(1):4858. DOI:10.1038/s41467-020-18640-0; Kim J., Mouw K.W., Polak P. et al. Somatic ERCC2 mutations are associated with a distinct genomic signature in urothelial tumors. Nat Genet 2016;48(6):600–6. DOI:10.1038/ng.3557; Galsky M.D., Daneshmand S., Chan K.G. et al. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC): HCRN GU16-257. J Clin Oncol 2021;39:4503.; Yang D., Khan S., Sun Y. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011;306(14):1557–65. DOI:10.1001/jama.2011.1456; Sakai W., Swisher E.M., Karlan B.Y. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451(7182):1116–20. DOI:10.1038/nature06633; Tutt A., Tovey H., Cheang M.C.U. et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24(5):628–37. DOI:10.1038/s41591-018-0009-7; Robertson A.G., Kim J., Al-Ahmadie H. et al. TCGA Research Network. Comprehensive molecular characterization of muscleinvasive bladder cancer. Cell 2017;171(3):540–56.e25.; Carlo M.I., Ravichandran V., Srinavasan P. et al. Cancer susceptibility mutations in patients with urothelial malignancies. J Clin Oncol 2020;38(5):406–14. DOI:10.1200/JCO.19.01395; Nassar A.H., Abou Alaiwi S., AlDubayan S.H. et al. Prevalence of pathogenic germline cancer risk variants in high-risk urothelial carcinoma. Genet Med 2020;22(4):709–18. DOI:10.1038/s41436-019-0720-x; Mullane S.A., Werner L., Guancial E.A. et al. Expression levels of DNA damage repair proteins are associated with overall survival in platinum-treated advanced urothelial carcinoma. Clin Genitourin Cancer 2016;14(4):352–9. DOI:10.1016/j.clgc.2015.12.029; Lord C.J., Ashworth A. RAD51, BRCA2 and DNA repair: a partial resolution. Nat Struct Mol Biol 2007;14(6):461–2. DOI:10.1038/nsmb0607-461; Plimack E.R., Dunbrack R.L., Brennan T.A. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur Urol 2015;68(6):959–67. DOI:10.1016/j.eururo.2015.07.009; Miron B., Ross E.A., Anari F. et al. Defects in DNA repair genes and long-term survival in cisplatin-based neoadjuvant chemotherapy for muscle invasive bladder cancer (MIBC). J Clin Oncol 2019;37:4536.; Teo M.Y., Bambury R.M., Zabor E.C. et al. DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma. Clin Cancer Res 2017;23(14):3610–8. DOI:10.1016/j.urolonc.2018.05.011; Rosenberg J.E., Ballman K.A., Halabi S. et al. Randomized phase III trial of gemcitabine and cisplatin with bevacizumab or placebo in patients with advanced urothelial carcinoma: results of CALGB 90601 (Alliance). J Clin Oncol 2021;39(22):2486–96. DOI:10.1200/JCO.21.00286; Geynisman D.M., Abbosh P., Ross E.A. et al. A phase II trial of risk enabled therapy after initiating neoadjuvant chemotherapy for bladder cancer (RETAIN BLADDER): interim analysis. J Clin Oncol 2021;39(6):397.; Powles T., Loriot Y., Bellmunt J. et al. 699O avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): association between clinical outcomes and exploratory biomarkers. Ann Oncol 2020;31(4):552–3. DOI:10.1016/j.annonc.2020.08.771; Powles T., Assaf Z.J., Davarpanah N. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;595(7867): 432–7. DOI:10.1038/s41586-021-03642-9; Bellmunt J., Hussain M., Gschwend J.E. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2021;22(4):525–37. DOI:10.1016/S1470-2045(21)00004-8; Kamoun A., de Reyniès A., Allory Y. et al. Bladder Cancer Molecular Taxonomy Group. A consensus molecular classification of muscleinvasive bladder cancer. Eur Urol 2020;77(4):420–33. DOI:10.1016/j.eururo.2019.09.006; Wang L., Gong Y., Saci A. et al. Fibroblast growth factor receptor 3 alterations and response to PD-1/PD-L1 blockade in patients with metastatic urothelial cancer. Eur Urol 2019;76(5):599–603. DOI:10.1016/j.eururo.2019.06.025; Rose T.L., Weir W.H., Mayhew G.M. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br J Cancer 2021;125(9):1251–60. DOI:10.1038/s41416-021-01488-6; Powles T., Carroll D., Chowdhury S. et al. An adaptive, biomarkerdirected platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. Nat Med 2021;27(5):793–801. DOI:10.1038/s41591-021-01317-6; Sharma P., Retz M., Siefker-Radtke A. et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017;18(3):312–22. DOI:10.1016/S1470-2045(17)30065-7; Powles T., O’Donnell P.H., Massard C. et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 Open-label study. JAMA Oncol 2017;3(9):e172411. DOI:10.1001/jamaoncol.2017.2411; FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking keytruda (pembrolizumab) or tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. Available at: https://www.fda.gov/drugs/drugsafety-and-availability/fda-alerts-health-care-professionals-andoncologyclinical-investigators-about-efficacy-issue.; Galsky M.D., Necchi A., Sridhar S.S. et al. A phase III, randomized, open-label, multicenter, global study of first-line durvalumab plus standard of care (SoC) chemotherapy and durvalumab plus tremelimumab, and SoC chemotherapy versus SoC chemotherapy alone in unresectable locally advanced or metastatic urothelial cancer (NILE). J Clin Oncol 2021;39(6):TPS504. DOI:10.1200/JCO.2021.39.6_suppl.TPS504; Rui X., Gu T.T., Pan H.F., Zhang H.Z. Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: a metaanalysis. Int Immunopharmacol 2019;67:378–85. DOI:10.1016/j.intimp.2018.12.018; Litchfield K., Reading J.L., Puttick C. et al. Meta-analysis of tumorand T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 2021;184(3):596–614.e14. DOI:10.1016/j.cell.2021.01.002; Powles T., Durán I., van der Heijden M.S. et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2018;391(10122):748–57. DOI:10.1016/S0140-6736(17)33297-X; Hirsch F.R., McElhinny A., Stanforth D. et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the blueprint PD-L1 IHC assay comparison project. J Thorac Oncol 2017;12(2):208–22. DOI:10.1016/j.jtho.2016.11.2228; Ratcliffe M.J., Sharpe A., Midha A. et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res 2017;23(14):3585–91. DOI:10.1158/1078-0432.CCR-16-2375; Tsao M.S., Kerr K.M., Kockx M. et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of blueprint phase 2 project. J Thorac Oncol 2018;13(9):1302–11. DOI:10.1016/j.jtho.2018.05.013; Decazes P., Bohn P. Immunotherapy by immune checkpoint inhibitors and nuclear medicine imaging: current and future applications. Cancers (Basel) 2020;12(2):371. DOI:10.3390/cancers12020371; Bensch F., van der Veen E.L., Lub-de Hooge M.N. et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nat Med 2018;24(12):1852–8. DOI:10.1038/s41591-018-0255-8; Niemeijer A.N., Leung D., Huisman M.C. et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with nonsmallcell lung cancer. Nat Commun 2018;9(1):4664. DOI:10.1038/s41467-018-07131-y; Alexandrov L.B., Nik-Zainal S., Wedge D.C. et al. Signatures of mutational processes in human cancer. Nature 2013;500(7463): 415–21. DOI:10.1016/j.celrep.2012.12.008; Rosenberg J.E., Hoffman-Censits J., Powles T. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387(10031):1909–20. DOI:10.1016/S0140-6736(16)00561-4; Samstein R.M., Lee C.H., Shoushtari A.N. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet 2019;51(2):202–6. DOI:10.1038/s41588-018-0312-8; Mariathasan S., Turley S.J., Nickles D. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 2018;554(7693):544–8. DOI:10.1038/nature25501; Bellmunt J., de Wit R., Fradet Y. et al. 747P association of TMB with efficacy of pembrolizumab (pembro) in patients (pts) with advanced urothelial cancer (UC): results from KEYNOTE-045 and KEYNOTE-052. Ann Oncol 2020;31(suppl 4):580–1. DOI:10.1016/j.annonc.2020.08.819; FDA approves pembrolizumab for adults and children with TMB-H solid tumors. Available at: https://www.fda.gov/drugs/drugapprovals-and-databases/fda-approves-pembrolizumab-adults-and-children-tmb-h-solid-tumors.; Yarchoan M., Albacker L.A., Hopkins A.C. et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight 2019;4(6):126908. DOI:10.1172/jci.insight.126908; Galsky M.D., Saci A., Szabo P.M. et al. Nivolumab in patients with advanced platinum-resistant urothelial carcinoma: efficacy, safety, and biomarker analyses with extended follow-up from checkmate 275. Clin Cancer Res 2020;26(19):5120–8. DOI:10.1158/1078-0432.CCR-19-416; Galsky M.D., Banchereau R., Hamidi H.R. et al. Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study. J Clin Oncol 2020;38:5011. DOI:10.1200/JCO.2020.38.15_suppl.5011; Valero C., Lee M., Hoen D. et al. Response rates to anti-PD-1 Immunotherapy in microsatellite-stable solid tumors with 10 or more mutations per megabase. JAMA Oncol 2021;7(5):739–43. DOI:10.1001/jamaoncol.2020.7684; McGranahan N., Rosenthal R., Hiley C.T. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 2017;171(6):1259–71.e11. DOI:10.1016/j.cell.2017.10.001; Zhang J., Bu X., Wang H. et al. Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance. Nature 2018;553(7686):91–5. DOI:10.1038/nature25015; Wang L., Saci A., Szabo P.M. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat Commun 2018;9(1):3503. DOI:10.1038/s41467-018-05992-x; Calon A., Lonardo E., Berenguer-Llergo A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat Genet 2015;47(4):320–9. DOI:10.1038/ng.3225; Massagué J. TGFbeta in cancer. Cell 2008;134(2):215–30. DOI:10.1016/j.cell.2008.07.001; Lin R.L., Zhao L.J. Mechanistic basis and clinical relevance of the role of transforming growth factor-β in cancer. Cancer Biol Med 2015;12(4):385–93. DOI:10.7497/j.issn.2095-3941.2015.0015; O’Donnell P.H., Grivas P., Balar A.V. et al. Biomarker findings and mature clinical results from KEYNOTE-052: first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). J Clin Oncol 2017;35:4502. DOI:10.1200/JCO.2017.35.15_SUPPL.4502; Chen B., Khodadoust M.S., Liu C.L. et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol 2018;1711:243–59. DOI:10.1007/978-1-4939-7493-1_12; Aran D., Hu Z., Butte A.J. xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 2017;18(1):220. DOI:10.1186/s13059-017-1349-1; Cao J., Yang X., Li J. et al. Screening and identifying immunerelated cells and genes in the tumor microenvironment of bladder urothelial carcinoma: based on TCGA database and bioinformatics. Front Oncol 2019;9:1533. DOI:10.3389/fonc.2019.01533; Gohil S.H., Iorgulescu J.B., Braun D.A. et al. Applying highdimensional single-cell technologies to the analysis of cancer immunotherapy. Nat Rev Clin Oncol 2021;18(4):244–56. DOI:10.1038/s41571-020-00449-x; Guruprasad P., Lee Y.G., Kim K.H., Ruella M. The current landscape of single-cell transcriptomics for cancer immunotherapy. J Exp Med 2021;218(1):e20201574. DOI:10.1084/jem.20201574; Oh D.Y., Kwek S.S., Raju S.S. et al. Intratumoral CD4+ T cells mediate anti-tumor cytotoxicity in human bladder cancer. Cell 2020;181(7):1612–25.e13. DOI:10.1016/j.cell.2020.05.017; Chen Z., Zhou L., Liu L. et al. Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma. Nat Commun 2020;11(1):5077. DOI:10.1038/s41467-020-18916-5; Sfakianos J.P., Daza J., Hu Y. et al. Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers. Nat Commun 2020;11(1):2540. DOI:10.1038/s41467-020-16162-3; Mota J.M., Leite C.A., Souza L.E. et al. Post-sepsis state induces tumor-associated macrophage accumulation through CXCR4/CXCL12 and favors tumor progression in mice. Cancer Immunol Res 2016;4(4):312–22. DOI:10.1158/2326-6066.CIR-15-0170; Wang L., Sfakianos J.P., Beaumont K.G. et al. Myeloid cell-associated resistance to PD-1/PD-L1 blockade in urothelial cancer revealed through bulk and single-cell RNA sequencing. Clin Cancer Res 2021;27(15):4287–300. DOI:10.1158/1078-0432.CCR-20-4574; Siefker-Radtke A.O., Necchi A., Park S.H. et al. ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): long-term outcomes in BLC2001. J Clin Oncol 2020;38(15):5015. DOI:10.1200/JCO.2020.38.15_suppl.5015; Challita-Eid P.M., Satpayev D., Yang P. et al. Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. Cancer Res 2016;76(10):3003–13. DOI:10.1158/0008-5472.CAN-15-1313; Doronina S.O., Toki B.E., Torgov M.Y. et al. Development of potent monoclonal antibody auristatin conjugates for cancer therapy. Nat Biotechnol 2003;21(7):778–84. DOI:10.1038/nbt832; Itoh N., Ornitz D.M. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem 2011;149(2):121–30. DOI:10.1093/jb/mvq121; Plotnikov A.N., Schlessinger J., Hubbard S.R., Mohammadi M. Structural basis for FGF receptor dimerization and activation. Cell 1999;98(5):641–50. DOI:10.1016/s0092-8674(00)80051-3; Dieci M.V., Arnedos M., Andre F., Soria J.C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov 2013;3(3):264–79. DOI:10.1158/2159-8290.CD-12-0362; Di Martino E., Tomlinson D.C., Knowles M.A. A decade of FGF receptor research in bladder cancer: past, present, and future challenges. Adv Urol 2012;2012:429213. DOI:10.1155/2012/429213; Helsten T., Elkin S., Arthur E. et al. The FGFR landscape in cancer: analysis of 4,853 tumors by nextgeneration sequencing. Clin Cancer Res 2016;22(1):259–67. DOI:10.1158/1078-0432.CCR-14-3212; Costa R., Carneiro B.A., Taxter T. et al. FGFR3-TACC3 fusion in solid tumors: mini review. Oncotarget 2016;7(34):55924–38. DOI:10.1158/1078-0432.CCR-14-3212; Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507(7492):315–22. DOI:10.1038/nature12965; Siefker-Radtke A., Loriot Y., Siena S. et al. 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations. Ann Oncol 2020;31:584–5. DOI:10.1016/j.annonc.2020.08.824; Pal S.K., Rosenberg J.E., Hoffman-Censits J.H. et al. Efficacy of BGJ398, a fibroblast growth factor receptor 1–3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer Discov 2018;8(7):812–21. DOI:10.1158/2159-8290.CD-18-0229; Bellmunt J., Picus J., Kohli M. et al. FIERCE-21: phase 1b/2 study of docetaxel + b-701, a selective inhibitor of FGFR3, in relapsed or refractory (R/R) metastatic urothelial carcinoma (mUCC). J Clin Oncol 2018;36:4534.; Necchi A., Castellano D.E., Mellado B. et al. Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC). J Clin Oncol 2019;37:409.; Siefker-Radtke A.O., Currie G., Abella E. et al. FIERCE-22: clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis. J Clin Oncol 2019;37:4511. DOI:10.1200/JCO.2019.37.15_SUPPL.4511; Abdul-Karim R.M., Chaudhry A., Patrikidou A. et al. Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: results from the dose-finding phase Ib substudy of FIDES-02. J Clin Oncol 2021;39:437. DOI:10.1200/JCO.2021.39.6_suppl.437; Chaudhry A., Sternberg C.N., De Santis M. et al. FIDES-02, a phase Ib/II study of derazantinib (DZB) as monotherapy and combination therapy with atezolizumab (A) in patients with surgically unresectable or metastaticurothelial cancer (UC) and FGFR genetic aberrations. J Clin Oncol 2020;38:TPS590. DOI:10.1200/JCO.2020.38.6_suppl.TPS590; Quinn D.I., Petrylak D.P., Bellmunt J. et al. FORT-1: phase II/III study of rogaratinib versus chemotherapy (CT) in patients (pts) with locally advanced or metastatic urothelial carcinoma (UC) selected based on FGFR1/3 mRNA expression. J Clin Oncol 2020;38:489.; Rosenberg J.E., Gajate P., Morales-Barrera R. et al. Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatinineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and FGFR mRNA overexpression. J Clin Oncol 2020;38(15_suppl):5014. DOI:10.1200/JCO.2020.38.15_suppl.5014; Yue S., Li Y., Chen X. et al. FGFR–TKI resistance in cancer: current status and perspectives. J Hematol Oncol 2021;14(1):23. DOI:10.1186/s13045-021-01040-2; Goyal L., Saha S.K., Liu L.Y. et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov 2017;7(3):252–63. DOI:10.1158/2159-8290.CD-16-1000; Datta J., Damodaran S., Parks H. et al. Akt activation mediates acquired resistance to fibroblast growth factor receptor inhibitor BGJ398. Mol Cancer Ther 2017;16(4):614–24. DOI:10.1158/1535-7163.MCT-15-1010; Wang L., Šuštić T., Leite de Oliveira R. et al. A functional genetic screen identifies the phosphoinositide 3-kinase pathway as a determinant of resistance to fibroblast growth factor receptor inhibitors in FGFR mutant urothelial cell carcinoma. Eur Urol 2017;71(6):858–62. DOI:10.1016/j.eururo.2017.01.021; Ryan M.R., Sohl C.D., Luo B., Anderson K.S. The FGFR1 V561M gatekeeper mutation drives AZD4547 resistance through STAT3 activation and EMT. Mol Cancer Res 2019;17(2):532–43. DOI:10.1158/1541-7786.MCR-18-0429; Mandai K., Rikitake Y., Mori M., Takai Y. Nectins and nectin-like molecules in development and disease. Curr Top Dev Biol 2015;112:197–231. DOI:10.1016/bs.ctdb.2014.11.019; Chu C.E., Sjöström M., Egusa E.A. et al. Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. Clin Cancer Res 2021;27(18):5123–30. DOI:10.1158/1078-0432.CCR-20-4175; Hoffman-Censits J.H., Lombardo K.A., Parimi V. et al. Expression of nectin-4 in bladder urothelial carcinoma, in morphologic variants, and nonurothelial histotypes. Appl Immunohistochem Mol Morphol 2021;29(8):619–25. DOI:10.1097/PAI.0000000000000938; Rapani E., Sacchetti A., Corda D., Alberti S. Human TROP-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998;76(5):671–6. DOI:10.1002/(sici)1097-0215(19980529)76:53.0.co;2-7; Faltas B., Goldenberg D.M., Ocean A.J. et al. Sacituzumab govitecan, a novel antibody – drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer 2016;14(1):e75–9. DOI:10.1016/j.clgc.2015.10.002; Hurvitz S.A., Tolaney S.M., Punie K. et al. Biomarker evaluation in the phase 3 ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer. Cancer Res 2021;81:Abstract GS3–6.; Grivas P., Tagawa S.T., Bellmunt J. et al. TROPiCS-04: study of sacituzumab govitecan in metastatic or locally advanced unresectable urothelial cancer that has progressed after platinum and checkpoint inhibitor therapy. J Clin Oncol 2021;39:TPS498.; Drakaki A., Rezazadeh Kalebasty A., Lee J. et al. Phase Ib/II umbrella trial to evaluate the safety and efficacy of multiple 2L cancer immunotherapy (CIT) combinations in advanced/metastatic urothelial carcinoma (mUC): MORPHEUS-mUC. J Clin Oncol 2020;38:TPS591.; Iqbal N., Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014;2014:852748. DOI:10.1155/2014/852748; Coogan C.L., Estrada C.R., Kapur S., Bloom K.J. HER-2/neu protein overexpression and gene amplification in human transitional cellcarcinoma of the bladder. Urology 2004;63(4):786–90. DOI:10.1016/j.urology.2003.10.040; Latif Z., Watters A.D., Dunn I. et al. HER2/neu overexpression in the development of muscleinvasive transitional cell carcinoma of the bladder. Br J Cancer 2003;89(7):1305–9. DOI:10.1038/sj.bjc.6601245; Choudhury N.J., Campanile A., Antic T. et al. Afatinib activity in platinum-refractory metastatic urothelial carcinoma in patients with ERBB alterations. J Clin Oncol 2016;34(18):2165–71. DOI:10.1200/JCO.2015.66.3047; Font Pous A., Puente J., Castellano D.E. et al. Phase II trial of afatinib in patients with advanced/metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy (CT). J Clin Oncol 2018;36(6):TPS540. DOI:10.1200/JCO.2018.36.6_suppl.TPS540; Hainsworth J.D., Meric-Bernstam F., Swanton C. et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase IIa multiple basket study. J Clin Oncol 2018;36(6):536–42. DOI:10.1200/JCO.2017.75.3780; Sheng X., Zhou A., Yao X. et al. A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. J Clin Oncol 2019;37(15_suppl):4509. DOI:10.1200/JCO.2019.37.15_suppl.4509; Bob T., Makker V., Buonocore D.J. et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol 2018;36(15_suppl):2502. DOI:10.1200/JCO.2018.36.15_suppl.2502; Duan Y., Haybaeck J., Yang Z. Therapeutic potential of PI3K/AKT/mTOR pathway in gastrointestinal stromal tumors: rationale and progress. Cancers (Basel) 2020;12(10):2972. DOI:10.3390/cancers12102972; Sathe A., Nawroth R. Targeting the PI3K/AKT/mTOR pathway in bladder cancer. Methods Mol Biol 2018;1655:335–50. DOI:10.1007/978-1-4939-7234-0_23; Iyer G., Al-Ahmadie H., Schultz N. et al. Prevalence and cooccurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol 2013;31(25):3133–40. DOI:10.1200/JCO.2012.46.5740; Platt F.M., Hurst C.D., Taylor C.F. et al. Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer. Clin Cancer Res 2009;15(19):6008–17. DOI:10.1158/1078-0432.CCR-09-0898; Calderaro J., Rebouissou S., de Koning L. et al. PI3K/AKT pathway activation in bladder carcinogenesis. Int J Cancer 2014;134(8):1776–84. DOI:10.1002/ijc.28518; Cappellen D., Gil Diez de Medina S., Chopin D. et al. Frequent loss of heterozygosity on chromosome 10q in muscle-invasive transitional cell carcinomas of the bladder. Oncogene 1997;14(25):3059–66. DOI:10.1038/sj.onc.1201154; Aveyard J.S., Skilleter A., Habuchi T., Knowles M.A. Somatic mutation of PTEN in bladder carcinoma. Br J Cancer 1999;80(5–6):904–8. DOI:10.1038/sj.bjc.6690439; Tsuruta H., Kishimoto H., Sasaki T. et al. Hyperplasia and carcinomas in Pten-deficient mice and reduced PTEN protein in human bladder cancer patients. Cancer Res 2006;66(17):8389–96. DOI:10.1158/0008-5472.CAN-05-4627; Knowles M.A., Habuchi T., Kennedy W., Cuthbert-Heavens D. Mutation spectrum of the 9q34 tuberous sclerosis gene TSC1 in transitional cell carcinoma of the bladder. Cancer Res 2003;63(22):7652–6.; Milowsky M.I., Iyer G., Regazzi A.M. et al. Phase II study of everolimus in metastatic urothelial cancer. BJU Int 2013;112(4):462–70. DOI:10.1111/j.1464-410X.2012.11720.x; Bellmunt J., Lalani A.A., Jacobus S. et al. Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma. Br J Cancer 2018;119(6):707–12. DOI:10.1038/s41416-018-0261-0; Wagle N., Grabiner B.C., van Allen E.M. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov 2014;4(5):546–53. DOI:10.1158/2159-8290.CD-13-0353; Kim J.W., Milowsky M.I., Hahn N.M. et al. Sapanisertib, a dual mTORC1/2 inhibitor, for TSC1- or TSC2-mutated metastatic urothelial carcinoma (mUC). J Clin Oncol 2021;39(6):431.; McPherson V., Reardon B., Bhayankara A. et al. A phase 2 trial of buparlisib in patients with platinum-resistant metastatic urothelial carcinoma. Cancer 2020;126(20):4532–44. DOI:10.1002/cncr.33071; Flaherty K.T., Gray R.J., Chen A.P. et al. NCI-MATCH team. Molecular landscape and actionable alterations in a genomically guided cancer clinical trial: national cancer institute molecular analysis for therapy choice (NCI-MATCH). J Clin Oncol 2020;38(33):3883–94. DOI:10.1200/JCO.19.03010; Sathe A., Guerth F., Cronauer M.V. et al. Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy. Br J Cancer 2014;111(11):2103–13. DOI:10.1038/bjc.2014.534; Dickstein R.J., Nitti G., Dinney C.P. et al. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 2012;13(13):1325–38. DOI:10.4161/cbt.21793; Seront E., Rottey S., Filleul B. et al. Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma. BJU Int 2016;118(3):408–15. DOI:10.1111/bju.13415; Munster P., Aggarwal R., Hong D. et al. First-in-human phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin Cancer Res 2016;22(8):1932–9. DOI:10.1158/1078-0432.CCR-15-1665; Apolo A.B., Nadal R., Tomita Y. et al. Cabozantinib in patients with platinum-refractory metastatic urothelial carcinoma: an openlabel, single-centre, phase 2 trial. Lancet Oncol 2020;21(8):1099–109. DOI:10.1016/S1470-2045(20)30202-3; Apolo A.B., Nadal R., Girardi D.M. et al. Phase I study of cabozantinib and nivolumab alone or with ipilimumab for advanced or metastatic urothelial carcinoma and other genitourinary tumors. J Clin Oncol 2020;38(31):3672–84. DOI:10.1200/JCO.20.01652; https://oncourology.abvpress.ru/oncur/article/view/1676

Availability: https://oncourology.abvpress.ru/oncur/article/view/1676
https://doi.org/10.17650/1726-9776-2023-19-2-111-126